|  Keyword Search
| Date | Title | | | 03/08/10 | MDRNA, Inc. Announces Upcoming Investor Conference Presentations| BOTHELL, WA, Mar 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that J. Michael French, MDRNA's
President and Chief Executive Officer, will provide an overview of
the Company and its progress in key programs at the following
upcoming conferences:
-- The ROTH 22nd Annual OC Growth Stock Conference, on Monday, March 15 at
4:30 p.m. Pacific Time at the Ritz-Carlton in Dana Point, California;
... |
|  | | 02/08/10 | MDRNA, Inc. Reports Positive Results for Its Proprietary siRNA
Delivery Technology| Data Demonstrates the Potential for Long-Term Stability of Drug ProductsBOTHELL, WA, Feb 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that its lead delivery system
formulation demonstrated exceptional stability over a one year period
under a variety of conditions. The DiLA2 formulation maintained in
vivo knockdown activity with no observed loss in potency over the
course of the year-long study w... |
| | | 02/08/10 | MDRNA, Inc. Receives Compliance Extension From NASDAQ| BOTHELL, WA, Feb 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced that it received a letter on
February 5, 2010 from The NASDAQ Stock Market, Inc. notifying the
Company that, as a result of Securities and Exchanges Commission
(SEC) approved changes to NASDAQ Listing Rules, MDRNA now has a grace
period of 180 days from its initial notice of non-compliance in which
to regain compliance with the $50 million minimum Market Value of
Listed Securities (MVLS) for continued... |
| | | 02/01/10 | MDRNA, Inc. to Present at the 12th Annual BIO CEO & Investor
Conference| Will Also Participate in a Panel Discussion on RNAi-Based TechnologyBOTHELL, WA, Feb 01, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that it will present at the 12th
Annual BIO CEO & Investor Conference being held at the Waldorf
Astoria Hotel in New York City, New York. J. Michael French, MDRNA's
President and Chief Executive Officer, will provide an overview of
the Company and its progress in k... |
| | | 01/26/10 | MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer| MDRNA IP Estate Extends Into AsiaBOTHELL, WA, Jan 26, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins im... |
| | | 01/21/10 | MDRNA, Inc. Announces Allowance of European Patent Covering Formulations for Rapid Acting Insulin| Allowance Further Strengthens Intranasal IP Portfolio and Potential for Out-Licensing AssetsBOTHELL, WA, Jan 21, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.
"While our focus remains the development of R... |
| | | 01/19/10 | MDRNA Demonstrates Significantly Reduced Off-Target Activity for Proprietary RNAi-Based Compounds| Results Show Greater Target Specificity for Novel UsiRNA Constructs Based on Proprietary Unlocked Nucleobase Analog TechnologyBOTHELL, WA, Jan 19, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the presentation of data
highlighting the ability of the UsiRNA construct to significantly
minimize off-target effects while maintaining potent RNA Interference
(RNAi) activity. Narendra Vaish, Ph.D., MBA, Assoc... |
| | | 01/14/10 | MDRNA, Inc. Raises $5.5 Million in Registered Direct Offering| BOTHELL, WA, Jan 14, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into a definitive agreement with investors to raise gross proceeds of $5.5 million through a registered direct offering. Under the terms of the agreement, the Company will sell 5,385,557 shares of its common stock at $1.02125 per share. As part of the transaction, the investors also will receive warrants, with a 5-year term, to purchase 3,500,612 shares of common stock at an exerci... |
| | | 01/13/10 | MDRNA Reports Potent Anti-Tumor Activity Against Multiple Targets in Liver and Bladder Cancer| Announces Additional Early Collaborative Effort With Major International Pharmaceutical CompanyBOTHELL, WA, Jan 13, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, reported today in vivo data for bladder and liver cancer demonstrating further advancement of the Company's oncology programs. The Company reported a reduction in tumor growth in both liver and bladder cancers by targeting genes key to tumor progression, via both... |
| | | 12/24/09 | MDRNA, Inc. Announces Closing of $1 Million Bridge Loan| BOTHELL, WA, Dec 24, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the closing of a bridge loan
pursuant to a Note and Warrant Purchase Agreement. Under the terms of
the loan, the Company sold promissory notes in the aggregate
principal amount of $1.0 million and issued warrants to purchase an
aggregate of approximately 1.1 million shares of the Company's common
stock at $1.02 per share to certain ac... |
| | | 12/17/09 | MDRNA, Inc. Announces Patent Allowance Covering Methods for Targeted
siRNA Delivery to the Lung| Patent Strengthens MDRNA's RNAi Delivery IP EstateBOTHELL, WA, Dec 17, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that the U.S. Patent and
Trademark Office (USPTO) has allowed patent application U.S.
11/627,863 covering methods for the delivery of a broad array of
compounds with pharmacological (biological) activity, including
siRNAs, using proprietary targeting peptides that have preferential
bin... |
| | | 12/03/09 | MDRNA, Inc. Presents Positive Efficacy and Tolerability Data in Non-Human Primates With Proprietary siRNA Compounds| New Data Demonstrates Evidence of Potent Anti-Tumor Activity Against Multiple Gene Targets in Multiple Rodent Oncology Models
BOTHELL, WA, Dec 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced presentation of data related to
its non-human primate and oncology programs at the Informa Life
Science 10th Annual Conference, EuroTIDES, taking place in Amsterdam,
The Netherlands. Michael V. Templin, Ph.D.,... |
| | | 12/01/09 | MDRNA, Inc. Presents to International Webinar Audience on Innovations in Oncology Drug Discovery, Development & Delivery| Presentation Highlights Versatility and Breadth of Its Proprietary siRNA Drug Discovery and Delivery Platform BOTHELL, WA, Dec 01, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced a webinar presentation related
to its RNAi oncology programs at the Innovations in Oncology Drug
Discovery, Development and Delivery Webinar Series to be presented on
December 1, at 1:00 pm EST. Roger Adami, Ph.D., Director,... |
| | | 11/24/09 | MDRNA Expands RNAi Bladder Cancer Program With the Vancouver Prostate Centre| Decision to Expand Based Upon Promising Pre-Clinical Results BOTHELL, WA, Nov 24, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the extension and expansion of
its collaboration with the Vancouver Prostate Centre (VPC), covering
the discovery and development of RNAi-based therapeutics for the
treatment of bladder cancer. Research conducted by scientists and
surgeons from both institutions demonstr... |
| | | 11/12/09 | MDRNA, Inc. Receives NASDAQ Notification| BOTHELL, WA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 6, 2009
it received a letter from The NASDAQ Stock Market, Inc. notifying the
Company that, for ten consecutive business days, based on the
Company's Market Value of Listed Securities (MVLS), it did not comply
with the $50 million minimum MVLS for continued listing on The NASDAQ
Global Market set forth in NASDAQ Marketplace Rule 5450(b)(3)(A). The
Company has a grace period of 9... |
| | | 11/12/09 | MDRNA, Inc. Announces Third Quarter 2009 Financial Results| Highlights Third Quarter and Recent Corporate Accomplishments BOTHELL, WA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and nine-month periods ended September 30, 2009. Net loss for
the third quarter of 2009 was approximately $7.0 million or $0.17 per
share, compared to a net loss of approximately $16.1 million or $0.52
per share for the same period of 2008. The net loss for the nine
months ended September 30, 2009 wa... |
| | | 11/05/09 | MDRNA, Inc. to Hold Third Quarter 2009 Results Conference Call on Thursday, November 12, 2009 at 4:30 pm Eastern Time| BOTHELL, WA, Nov 05, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
November 12, 2009, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to
provide a business update and discuss financial results for the 3rd
quarter ended September 30, 2009. To participate in the live
conference call, U.S. residents should dial 866-543-6405 and
international callers should dial 617-213-8897. The p... |
| | | 10/29/09 | MDRNA to Present Data on Tumor Reduction at Cancer Therapy Conference| Results Demonstrate Sustained Reduction in Liver and Bladder Tumor Growth via RNAi Mediated Knockdown of SurvivinBOTHELL, WA, Oct 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the presentation of data related
to its RNAi oncology programs at the 24th Annual Meeting of the
International Society for Biological Therapy of Cancer, taking place
October 28-31, 2009 at the Gaylord National Hotel and Conve... |
| | | 10/22/09 | MDRNA to Present at the 8th Annual BIO Investor Forum| BOTHELL, WA, Oct 22, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that J. Michael French, MDRNA's
President and Chief Executive Officer, will deliver a corporate
presentation and business update at the 8th Annual BIO Investor
Forum. The presentation will take place on Thursday, October 29,
2009 at 9:00am Pacific Time (12:00pm Eastern Time) at the Palace
Hotel in San Francisco, California.
To acces... |
| | | 10/12/09 | MDRNA Reports UsiRNA Reduces Tumor Growth In Vivo| Demonstrates RNAi-Mediated Knockdown of Previously "Non-Druggable" Targets in Liver and Bladder Cancers BOTHELL, WA, Oct 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today presented new in vivo data demonstrating
continued progress in the advancement of the Company's oncology
program. J. Michael French, President and CEO, reported that MDRNA's
UsiRNAs, delivered by the Company's DiLA2 platform, down-regulated... |
| | | 09/29/09 | MDRNA Announces Patent Allowance Covering an siRNA With Therapeutic Potential for Oncology and Other Indications| siRNA Directed Against JAM-1 Gene Also Has Potent Drug Delivery Potential BOTHELL, WA, Sep 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that the U.S. Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for patent
application U.S. 11/624,630 covering an siRNA directed against a
junctional adhesion molecule-1 (JAM-1) gene.
The siRNA of the allowed claim has a broad array of pot... |
| | | 09/08/09 | MDRNA Adds June D. Ameen to Management Team as Vice President, Corporate Development| BOTHELL, WA, Sep 08, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that June D. Ameen, RN,
MBA, will join the Company as Vice President, Corporate Development
reporting to the President & CEO. Ms. Ameen will lead the alliance
management, business development, technology evaluation and strategic
partnering efforts for the Company.
"We are extremely pleased to have June join our management team,"
said Michael French, President and CEO at MDRNA. "Recently, we enga... |
| | | 09/03/09 | MDRNA, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference| MDRNA to Also Participate on a Panel of Leading RNAi Companies BOTHELL, WA, Sep 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at
the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday,
September 10, 2009, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific
Time) at the New York Palace Hotel in New York City. J. Michael
French, MDRNA's President and Chief Executive Officer, will present a
corporate overview and business updat... |
| | | 08/11/09 | MDRNA, Inc. Appoints James M. Karis to Its Board of Directors| BOTHELL, WA, Aug 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has
been appointed to the Company's Board of Directors. His appointment
brings the number of MDRNA board members to six.
"I am pleased to welcome James Karis to MDRNA's Board of Directors,"
stated Bruce R. Thaw, Chairman of the Board of Directors. "James has
spent 30 years in the pharmaceutical, healthcare services and medical
device industries and brings extensive corporate ... |
| | | 08/06/09 | MDRNA, Inc. to Present at the 29th Canaccord Adams Global Growth Conference| BOTHELL, WA, Aug 06, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at
the 29th annual Canaccord Adams Global Growth Conference on
Wednesday, August 12, 2009, at 3:00 p.m. Eastern Time (12:00 p.m.
Pacific Time) at the InterContinental Hotel in Boston, Massachusetts.
J. Michael French, MDRNA's President and Chief Executive Officer,
will present a corporate overview and business update.
To access the live audio webcast for this conference, pl... |
| | | 08/03/09 | MDRNA, Inc. Reports Positive In Vivo Data Demonstrating That Its UsiRNAs Are Highly Potent Against Metabolic and Oncology Targets| UsiRNAs Work Via the RNAi Mechanism of Action but With Minimal Off-Target Activity BOTHELL, WA, Aug 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive data on its
proprietary UsiRNA technology, demonstrating that its UsiRNAs are
highly potent against metabolic disease and cancer targets in rodent
models. Further, the data establish that the knockdown of these
targets is achieved via an RNAi-mediated process. Of particular
importance is that the data ... |
| | | 07/29/09 | MDRNA, Inc. Announces Second Quarter 2009 Financial Results| BOTHELL, WA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and six-month periods ended June 30, 2009. Net loss for the
second quarter of 2009 was approximately $7.5 million or $0.21 per
share, compared to a net loss of approximately $14.3 million or $0.48
per share for the same period of 2008. The net loss for the six
months ended June 30, 2009 was approximately $0.3 million or $0.01
per share, compared to approximately $... |
| | | 07/29/09 | MDRNA, Inc. to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference| BOTHELL, WA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at
the BMO Capital Markets 9th Annual Focus on Healthcare Conference on
Wednesday, August 5, 2009, at 2:15 p.m. Eastern Time (11:15 a.m.
Pacific Time) at the Millennium Broadway Hotel in New York City. J.
Michael French, MDRNA's President and Chief Executive Officer, will
present a corporate overview and business update.
To access the live audio webcast for this conference,... |
| | | 07/23/09 | MDRNA, Inc. to Hold Second Quarter 2009 Results Conference Call on Thursday, July 30, 2009, at 8:30 a.m. Eastern Time| BOTHELL, WA, Jul 23, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
July 30, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
provide a business update and discuss financial results for the 2nd
quarter ended June 30, 2009. To participate in the live conference
call, U.S. residents should dial 800-510-9836 and international
callers should dial 617-614-3670. The partic... |
| | | 07/14/09 | MDRNA Appoints New Chief Financial Officer| BOTHELL, WA, Jul 14, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the appointment of Peter
S. Garcia as Chief Financial Officer and Secretary, reporting to the
President and CEO. Mr. Garcia will lead and direct corporate
financial and financing activities, investor and public relations
efforts, as well as facilities and information technology operations
for the Company.
"We are extremely pleased to add an individual of Pete's caliber to
our management team,"... |
| | | 06/23/09 | MDRNA, Inc. Regains Full Compliance With All Marketplace Rules to Remain on the NASDAQ Global Market| Receives Letter From NASDAQ Regarding Compliance With NASDAQ Marketplace Rule 5450(b)(2)(A)BOTHELL, WA, Jun 23, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on June 22, 2009,
it received a letter from The NASDAQ Stock Market, LLC notifying the
Company that it has regained full compliance with all requirements
for remaining on The NASDAQ Global Market, specifically NASDAQ
Marketplace Rule 5450(b)(2) (the "market value standard"), which
requires, among othe... |
| | | 06/19/09 | MDRNA, Inc. Gains Full Financial and Transactional Control of Its Proprietary UNA Technology| Amends Agreement With RiboTask to Eliminate All Milestone and Royalty PaymentsBOTHELL, WA, Jun 19, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it now has full
financial and transactional control over the use of its proprietary
UNA (Unlocked Nucleobase Analog) technology for the development of
RNAi-based therapeutics. The Company completed negotiations with
RiboTask ApS to eliminate all downstream financial consideration to
RiboTask resulting from collabo... |
| | | 06/16/09 | MDRNA, Inc. Announces Full Repayment of GE Capital Debt| BOTHELL, WA, Jun 16, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has repaid all of
its remaining debt to General Electric Capital Corporation (GECC)
under the January 2009 Loan and Security Agreement.
"I am pleased we have met our commitment to shareholders to eliminate
the Company's remaining term debt obligations prior to the start of
the third quarter," stated J. Michael French, President and CEO. "In
less than five months time, we retired a $5.5 m... |
| | | 06/12/09 | MDRNA, Inc. Announces Closing of $10.5 Million Registered Direct Financing| BOTHELL, WA, Jun 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has closed its
previously announced sale of 5.25 million shares of its common stock
and warrants to purchase 5.25 million shares of its common stock for
gross proceeds of $10.5 million. MDRNA sold the shares for $2.00 per
share. The exercise price of the warrants is $2.38 per share. The
warrants, with a five and a half year term, will be exercisable six
months from June 12, 2009. MDRNA p... |
| | | 06/11/09 | MDRNA, Inc. Granted Request to Remain Listed on The NASDAQ Global Market| BOTHELL, WA, Jun 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on Wednesday, June
10, 2009, the NASDAQ Hearings Panel granted the request of the
Company to remain listed on The NASDAQ Global Market and that the
Company had until August 31, 2009 to establish a minimum $10.0
million in stockholders' equity or demonstrate compliance with one of
the alternative listing criteria per NASDAQ Marketplace Rule 5450(b).
The Company announced on March 6, 2009 tha... |
| | | 06/10/09 | MDRNA, Inc. Raises $10.5 Million in Registered Direct Offering| BOTHELL, WA, Jun 10, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it entered into
definitive agreements on June 9, 2009 with existing investors to
raise gross proceeds of $10.5 million though a registered direct
offering. Under terms of the agreements, the Company will sell 5.25
million shares of its common stock at $2.00 per share. As part of the
transaction, the investors also will receive warrants, with a five
and a half year term, to purchase 5.25 mil... |
| | | 06/09/09 | MDRNA, Inc. Receives Full FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis| Par Pharmaceutical Companies, Inc. Launches ProductBOTHELL, WA, Jun 09, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has obtained full
U.S. Food and Drug Administration (FDA) approval of its Abbreviated
New Drug Application (ANDA) for generic calcitonin-salmon nasal spray
for the treatment of osteoporosis and that Par Pharmaceutical
Companies, Inc. (NYSE: PAR) has launched the product.
Calcitonin-salmon nasal spray, a legacy product developed by MDRNA i... |
| | | 06/08/09 | MDRNA, Inc. Reports Effective Local Delivery of a UsiRNA in an In Vivo Model of Bladder Cancer| Improved Performance of the DiLA2 siRNA Delivery Platform With Proprietary Peptide NanoparticlesBOTHELL, WA, Jun 08, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today in vivo data from a
bladder cancer model demonstrating effective localized delivery of a
UsiRNA to a solid tumor, thus further expanding the delivery
capabilities of the DiLA2 Platform. In addition, the Company reported
in vivo data demonstrating the ability of its proprietary
peptide-based nanoparticl... |
| | | 05/26/09 | MDRNA, Inc. Regains Compliance With NASDAQ Marketplace Rule 5450(a)(1)| BOTHELL, WA, May 26, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has received a
letter from the Listing Qualifications Department of The NASDAQ Stock
Market notifying the Company that because the closing bid price of
its common stock has been at or above $1.00 per share for at least
ten consecutive trading days, it has regained compliance with NASDAQ
Marketplace Rule 5450(a)(1) (formerly Marketplace Rule 4450(a)(5)).
"We are pleased to have regained c... |
| | | 05/21/09 | MDRNA, Inc. Resizes Board of Directors| BOTHELL, WA, May 21, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that as a result of its
2009 annual meeting on May 20, 2009, it has resized its Board of
Directors to establish a five person Board consistent with the
Company's cost containment efforts and overall focus as an RNAi drug
discovery and pre-clinical biotech company. The new Board of
Directors, effective immediately, will consist of Bruce R. Thaw, Esq.,
Chairman of the Board; Daniel Peters; James E... |
| | | 05/19/09 | MDRNA Reports Its Proprietary RNAi-Based Compounds Are Well Tolerated and Demonstrate High Potency Against Multiple Targets in Preclinical Studies| Data Confirm 90% Knockdown of Factor VII at 1 mg/kg With Duration of Effect up to 28 DaysBOTHELL, WA, May 19, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy
data showing that its proprietary UsiRNA constructs are highly potent
and highly specific against ApoB and Factor VII message. The data are
being presented today by Michael V. Templin, Ph.D., Vice President,
Discovery Research and Pharmaceutical Development of MDRNA, at the
TIDES Oli... |
| | | 05/15/09 | MDRNA, Inc. Appoints Beverly L. Davidson, Ph.D. and Carl Novina, M.D., Ph.D., to Its Scientific Advisory Board| BOTHELL, WA, May 15, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the appointment of
Beverly L. Davidson, Ph.D., and Carl Novina, M.D., Ph.D., to its
Scientific Advisory Board (SAB).
"The appointment of these outstanding scientists and opinion leaders
to our Scientific Advisory Board reflects our strong commitment to
scientific excellence as a premier RNAi therapeutics company," stated
Barry Polisky, Ph.D., Chief Scientific Officer. "We are particularly
pleas... |
| | | 05/14/09 | MDRNA, Inc. Announces First Quarter 2009 Financial Results| BOTHELL, WA, May 14, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
first quarter ended March 31, 2009.
"The first quarter of 2009 was a period of significant accomplishment
for the Company," stated J. Michael French, President and Chief
Executive Officer. "With the sale of our intranasal contract
manufacturing operations in Hauppauge, N.Y. on March 31st, we
completed our transition from a clinical stage delivery company to a
pre-clinic... |
| | | 05/11/09 | MDRNA, Inc. to Hold First Quarter 2009 Earnings Conference Call on Friday, May 15, 2009, at 8:30 a.m. Eastern Time| BOTHELL, WA, May 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Friday, May
15, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
discuss financial results for the first quarter ended March 31, 2009.
To participate in the live conference call, U.S. residents should dial
866-761-0748 and international callers should dial 617-614-2706. The
participant passcode for the live co... |
| | | 04/10/09 | MDRNA, Inc. Complies With NASDAQ Marketplace Rule 4350(b)(1)(B)| BOTHELL, WA, Apr 10, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that the Company's
independent registered public accounting firm included an explanatory
paragraph in their opinion on the Company's financial statements
included in the recently filed Annual Report on Form 10-K for the
year ended December 31, 2008, relating to the Company's ability to
continue as a going concern.
"As we described in our fourth quarter earnings call, we expected to
receive the... |
| | | 04/01/09 | MDRNA, Inc. Sells Contract Manufacturing Operation| Company Eliminates Cash Burn Related to Non-RNAi OperationsBOTHELL, WA, Apr 01, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into
an Asset Purchase Agreement with Par Pharmaceutical, Inc. (NYSE: PRX)
under which Par will acquire the Company's manufacturing facilities
in Hauppauge, New York as well as the Company's Abbreviated New Drug
Application (ANDA) for generic calcitonin-salmon nasal spray. Under
the terms of the Agreement, MDRNA will ... |
| | | 03/24/09 | MDRNA, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results| BOTHELL, WA, Mar 24, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
fourth quarter and year ended December 31, 2008.
"Since July 2008, MDRNA has made significant strides in its
transition from a clinical stage intranasal drug delivery company to
an RNAi drug discovery company," stated J. Michael French, President
& CEO of MDRNA. "In the second half of 2008, we reduced headcount,
terminated all legacy intranasal clinical programs; close... |
| | | 03/23/09 | MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology| BOTHELL, WA, Mar 23, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into
a licensing agreement with Novartis for MDRNA's liposomal technology
platform for siRNA delivery. MDRNA will receive $7.25 million in
upfront fees for the non-exclusive license. Additionally, the
companies have entered into a separate agreement, which provides
Novartis with an exclusive period to negotiate a research and
development collaboration and broader licensing r... |
| | | 03/20/09 | MDRNA, Inc. to Hold Year-End 2008 Earnings Conference on Tuesday, March 24, 2009, at 8:30 a.m. Eastern Time| BOTHELL, WA, Mar 20, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Tuesday,
March 24, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to
discuss financial results for the fourth quarter and fiscal year
ended December 31, 2008. To participate in the live conference call,
U.S. residents should dial 866-356-4441 and international callers
should dial 617-597-5396. The participant ... |
| | | 03/06/09 | MDRNA, Inc. Receives Delisting Notice From NASDAQ and Requests Hearing| BOTHELL, WA, Mar 06, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it received a NASDAQ
Staff Determination on March 4, 2009 indicating that the Company has
not regained compliance with Marketplace Rule 4450(a)(3) within the
extension period granted to the Company through March 3, 2009.
Marketplace Rule 4450(a)(3) requires a minimum $10.0 million in
stockholders' equity for continued listing on The NASDAQ Global
Market. In response to the March 4th letter... |
| | | 02/23/09 | MDRNA Successfully Silences Gene Targets in Animal Models Using Novel UsiRNA Constructs| Proprietary DiLA2 Platform Achieves In Vivo Knockdown of Multiple Metabolic Targets and Demonstrates Safe and Effective Delivery in Repeat Dose StudiesBOTHELL, WA, Feb 23, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy
data on its proprietary UsiRNA constructs demonstrating a dose
response which resulted in up to 90% knockdown of ApoB message in a
rodent model. The data were presented by Michael V. Templin, Ph.D.,
Vice President, Discove... |
| | | 02/13/09 | MDRNA, Inc. Announces Licensing Agreement With Roche| BOTHELL, WA, Feb 13, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into
an agreement with Roche (SWX: ROG) in which Roche will obtain a
non-exclusive license to a portion of MDRNA's technology platform for
the development of RNAi-based therapeutics. Terms of the agreement
were not disclosed.
"We are pleased to have Roche recognize the value of our drug
discovery platform," stated J. Michael French, President and Chief
Executive Officer of ... |
| | | 02/03/09 | MDRNA, Inc. Announces Receipt of Milestone Payment Under Amended Agreement With Amylin Pharmaceuticals, Inc. for Development and Commercialization of Intranasal Exenatide| MDRNA Continues to Monetize Intranasal Assets to Support On-Going RNAi-Based Therapeutic R&DBOTHELL, WA, Feb 03, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the achievement of a
milestone under an amended version of the June 2006 Development and
License Agreement with Amylin Pharmaceuticals, Inc. for the
development of intranasal exenatide. Under terms of the amended
agreement, Amylin has committed to advancing the program, resulting in
an accelerated $1 mill... |
| | | 12/15/08 | MDRNA, Inc. Announces Tentative FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis| BOTHELL, WA, Dec 15, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that the U.S. Food and
Drug Administration (FDA) has granted tentative approval of MDRNA's
Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon
nasal spray for the treatment of osteoporosis. Full FDA approval
would follow the completion of Apotex's 180-day exclusivity period,
or June 2009.
MDRNA's generic calcitonin-salmon nasal spray, a legacy product
developed ... |
| | | 12/03/08 | MDRNA Reports UNA-Modified siRNAs Effectively Silence Gene Targets in Animal Models| Proprietary DiLA2 Platform Continues to Demonstrate Safe and Effective In Vivo Delivery in Repeat Dose Studies BOTHELL, WA, Dec 03, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy
data on its proprietary Unlocked Nucleic Acid (UNA) siRNAs in animal
models, demonstrating up to 90% knockdown of ApoB. In addition, the
Company continues to report effective and safe delivery of its Lead
Candidate for hypercholesterolemia in an... |
| | | 11/25/08 | MDRNA, Inc. to Present at Piper Jaffray Healthcare Conference| BOTHELL, WA, Nov 25, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that J. Michael French,
President and CEO, will present at the Piper Jaffray Healthcare
Conference on Wednesday, December 3, 2008, at 3:00 p.m. Eastern Time
(12:00 p.m. Pacific Time), at the Palace Hotel in New York City.
To listen to an audio webcast during or after the presentation,
please go to: http://www.mdrnainc.com. A replay of the presentation
will be available for 30 days... |
| | | 11/24/08 | MDRNA, Inc. Receives NASDAQ Notification| BOTHELL, WA, Nov 24, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 18, 2008
it received a letter from The NASDAQ Stock Market, Inc. notifying the
Company that, based on the Company's stockholders' equity as reported
in the Quarterly Report on Form 10-Q for the period ended September
30, 2008, it does not comply with the $10 million minimum
stockholders' equity requirement for continued listing on The NASDAQ
Global Market set forth... |
| | | 11/13/08 | MDRNA, Inc. Announces Third Quarter 2008 Financial Results| BOTHELL, WA, Nov 13, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and nine-month periods ended September 30, 2008.
Revenue for the three months ended September 30, 2008 was $0.4
million, compared to $1.9 million for the three months ended September
30, 2007. Revenue for the nine months ended September 30, 2008 was
$2.4 million, compared to $11.7 million for the nine months ended
September 30, 2007. Revenue in 2008 ... |
| | | 11/06/08 | MDRNA, Inc. to Hold Third Quarter 2008 Earnings Conference Call on Thursday, November 13, 2008, at 4:30 p.m. Eastern Time| BOTHELL, WA, Nov 06, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
November 13, 2008, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
to discuss financial results for the third quarter ended September
30, 2008. To participate in the live conference call, U.S. residents
should dial 800-573-4754 and international callers should dial
617-224-4325. The participant... |
| | | 10/28/08 | MDRNA, Inc. Appoints Barry Polisky, Ph.D., as Chief Scientific Officer| Names New Chairman of the Board and Chair of the Scientific Advisory BoardBOTHELL, WA, Oct 28, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that Barry Polisky,
Ph.D., will join the Company as Chief Scientific Officer on January
2, 2009. Dr. Polisky replaces Steven C. Quay, M.D., Ph.D., Chief
Scientific Officer, Chairman of the Board of Directors and Chairman
of the Scientific Advisory Board, who will be leaving the Company on
November 30, 2008. Dr... |
| | | 10/22/08 | MDRNA, Inc. Acquires Patent Estate to Broaden Its RNAi Intellectual Property Portfolio| Acquires Rights to UNA Technology for Proprietary Stabilization of Both RISC and Dicer siRNAsBOTHELL, WA, Oct 22, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has acquired
intellectual property related to non-nucleotide chemistry (Unlocked
Nucleic Acid) technology from RiboTask ApS, a privately held Danish
company specializing in the development and synthesis of novel RNA
chemistries. The technology will permit MDRNA to stabilize and
provi... |
| | | 10/07/08 | MDRNA, Inc. Advances RNAi Pipeline With Selection of Lead Candidate for Hypercholesterolemia Program| MDR-04227 Is a Dicer Substrate siRNA Targeting Apolipoprotein B (ApoB)BOTHELL, WA, Oct 07, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has advanced its
RNAi pipeline with the selection of a Lead Candidate in its
hypercholesterolemia program targeting Apolipoprotein B (ApoB). The
compound, designated MDR-04227, was developed using MDRNA's propriety
drug discovery engine, which is built on a broad and enabling
intellectual property estate a... |
| | | 09/25/08 | MDRNA, Inc. Receives NASDAQ Notice Letter| BOTHELL, WA, Sep 25, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on September 19,
2008, it received a notification letter from the Listing
Qualifications Department of the NASDAQ Stock Market. The notice, in
accordance with NASDAQ Marketplace Rule 4450(a)(5) "Minimum Bid Price
Requirement," states that the Company's common stock has closed below
$1.00 per share for 30 consecutive business days. This notification
has no immediate effect on t... |
| | | 09/23/08 | MDRNA, Inc. to Present at the Maxim Group Growth Conference| BOTHELL, WA, Sep 23, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that J. Michael French,
CEO, will present at the Maxim Group Growth Conference on Tuesday,
October 7, 2008, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time)
at the Grand Hyatt Hotel in New York City.
"We appreciate the opportunity to present the growing investment
opportunity at MDRNA to security analysts, fund managers and
institutional investors at the Maxim Group Growth Confe... |
| | | 09/15/08 | J. Michael French, CEO of MDRNA, Inc., Appointed to Board of Directors and Will Become President Effective October 1, 2008| BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 15, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that J. Michael French, CEO, has been
appointed to the Company's Board of Directors. Mr. French, 48, will
also assume the additional role of President effective October 1,
2008.
"On behalf of the Board of Directors, I am pleased to welcome
Michael to MDRNA's Board," stated Bruce R. Thaw, Lead Independent
Director of MDRNA. "Since joining the Company as CEO in June, Michael
has demonstrated... |
| | | 09/04/08 | MDRNA Receives Additional Funding from National Institutes of Health| - Five Year Grant Continues Funding Research in RNAi Inhibition of
Influenza -
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 4, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that the National Institutes of Health
(NIH) has awarded the Company over $350,000 for further development of
the Company's siRNA therapeutics program to prevent and treat
influenza. These funds are part of a five-year grant totaling $1.9
million that the NIH awarded the Company in Septe... |
| | | 08/19/08 | MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides| - Novel Cationic Peptides from University of Michigan improve
siRNA delivery -
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 19, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that it has signed an exclusive license
agreement to intellectual property from the University of Michigan
covering cationic peptides for enhanced delivery of nucleic acids.
Terms of the agreement were not disclosed.
"The University of Michigan peptides have unique characteristics
t... |
| | | 08/13/08 | MDRNA, Inc. Lead Candidate Demonstrates In Vivo Efficacy against Seasonal and Pandemic Flu Strains| - Intranasal administration of an siRNA in a proprietary delivery
system produces greater than 99% reduction in viral titers and a 100%
survival benefit against Avian Flu -
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 13, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today positive in vivo efficacy data on its
proprietary RNAi-based therapeutic for the treatment of multiple
strains of influenza A virus in animal models. The in vivo data were
presented by Shaguna Seth, Ph.D., Associ... |
| | | 08/04/08 | MDRNA, Inc. Announces Second Quarter 2008 Financial Results and Additional Corporate Restructuring| BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 4, 2008--MDRNA, Inc.
(Nasdaq: MRNA) today reported financial results for the three- and
six-month periods ended June 30, 2008, and a further corporate
restructuring.
Revenue for the three months ended June 30, 2008, was $0.7
million, compared to $4.9 million for the three months ended June 30,
2007. Revenue for the six months ended June 30, 2008 was $2.0 million,
compared to $9.9 million for the six months ended June 30, 2007.
Revenue in 2008... |
| | | 08/01/08 | MDRNA, Inc. Demonstrates In Vivo Efficacy with Proprietary DiLA2 Delivery Platform| Systemic delivery of 3-stranded siRNA constructs formulated in
proprietary liposomes decreases serum cholesterol
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 1, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today positive in vivo efficacy data using a
novel combination of a meroduplex siRNA and MDRNA's proprietary
lipid-based delivery platform, the DiLA2 Platform. The data presented
today by Narendra Vaish, Ph.D., MBA, Senior Research Scientist and
Group Leader - RNAi Platform Te... |
| | | 07/31/08 | MDRNA Announces Phase 2 Trial of PYY(3-36) Does not Meet Weight Loss Endpoint| - Data demonstrate effective delivery of PYY -
BOTHELL, Wash.--(BUSINESS WIRE)--July 31, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today results from a Phase 2 clinical trial
evaluating PYY(3-36) Nasal Spray (PYY) for the treatment of obesity.
The data indicate that PYY did not meet the primary efficacy endpoint
of a dose response of weight loss vs. PYY dose, nor did PYY meet the
secondary efficacy endpoint of greater weight loss than the active
control, sibutramine (Meridia(R)).... |
| | | 07/28/08 | MDRNA, Inc. to Hold Second Quarter 2008 Earnings Conference on Monday, August 4, 2008, at 4:30 p.m. Eastern Time| BOTHELL, Wash.--(BUSINESS WIRE)--July 28, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that it will host a conference call
with investors and security analysts on Monday, August 4, 2008, at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial
results for the second quarter ended June 30, 2008. To participate in
the live conference call, U.S. residents should dial 866-825-3354 and
international callers should dial 617-213-8063. The participant code
for the live conf... |
| | | 07/28/08 | MDRNA, Inc. to Present at BMO Capital Markets 2008 Focus on Healthcare Conference| BOTHELL, Wash.--(BUSINESS WIRE)--July 28, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that it will present at the BMO Capital
Markets Focus on Healthcare Conference on Wednesday, August 6, 2008,
at 11:15 a.m. Eastern Time (8:15 a.m. Pacific Time) at the Millennium
Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log
on to MDRNA's Web site at http://www.mdrnainc.com approximately 15
minutes prior to the presentation in order to regi... |
| | | 06/23/08 | MDRNA, Inc. Announces Option Grant to Its Chief Executive Officer under NASDAQ Marketplace Rule 4350| BOTHELL, Wash.--(BUSINESS WIRE)--June 23, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that in accordance with NASDAQ
Marketplace Rule 4350(i)(1)(A)(iv), the Compensation Committee of the
Board of Directors approved an inducement grant of stock options to J.
Michael French, MDRNA's Chief Executive Officer, in connection with
the employment agreement that MDRNA entered into with Mr. French. On
June 23, 2008, Mr. French was granted options to purchase up to
1,260,000 shares of Commo... |
| | | 06/10/08 | Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer| BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq:
NSTK - News) announced that having acquired shareholder approval, effective
today the Company has changed its name to MDRNA, Inc. (“MDRNA”). MDRNA will
leverage its scientific and intellectual property (IP) position surrounding
the research, development and delivery of Dicer substrates and “Meroduplex”
(mdRNA) RNA interference (RNAi) drug candidates to build an industry-leading
position in the d... |
| | | 06/09/08 | Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting| - Ultra rapid acting intranasal insulin offers mealtime glucose
control with significantly reduced risk of hypoglycemia -
BOTHELL, Wash.--(BUSINESS WIRE)--June 9, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a
Phase II clinical trial demonstrating that its ultra rapid acting
intranasal insulin was both superior to usual therapy (oral
anti-diabetic medicines and/or basal insulin) and non-inferior to
insulin aspart (NovoLog(R)), a rap... |
| | | 05/08/08 | Nastech Announces First Quarter 2008 Financial Results| BOTHELL, Wash.--(BUSINESS WIRE)--May 8, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial
results for the quarter ended March 31, 2008.
Revenue for the three months ended March 31, 2008, was $1.3
million, compared to $5.0 million for the three months ended March 31,
2007. The 2008 period included $0.1 million in government grant
revenue and $0.5 million in Nascobal(R) product sales. The $0.7
million in license and research fee revenue was primaril... |
| | | 05/01/08 | Nastech to Release First Quarter Financial Results and Host Webcast on Thursday, May 8, 2008| BOTHELL, Wash.--(BUSINESS WIRE)--May 1, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its
first quarter financial results will be released on Thursday, May 8,
2008, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). Management
will then host a conference call beginning at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss first quarter financial results
and provide a corporate update.
To participate in the live conference call, U.S. residen... |
| | | 04/25/08 | Nastech Pharmaceutical Company Inc. Raises $7.93 Million in Registered Direct Offering| BOTHELL, Wash.--(BUSINESS WIRE)--April 25, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
entered into definitive agreements with new and existing investors to
raise gross proceeds of $7,932,500 though a registered direct
offering. Under terms of the agreement, the Company will sell
4,585,260 shares of its common stock at $1.73 per share. As part of
the transaction, the investors also will receive warrants, with a
7-year term, to purchase 4,585,26... |
| | | 03/27/08 | Nastech Pharmaceutical Company Inc. Announces Appointment of Gunter Blobel, M.D., Ph.D., to its MDRNA, Inc. Scientific Advisory Board| BOTHELL, Wash.--(BUSINESS WIRE)--March 27, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that Gunter
Blobel, M.D., Ph.D., has joined the Scientific Advisory Board of
MDRNA, Inc., Nastech's wholly-owned subsidiary for the development of
RNAi technology and therapeutics. Dr. Blobel is a Howard Hughes
Medical Institute investigator at The Rockefeller University in New
York City. In 1999, Dr. Blobel was awarded the Nobel Prize in
Physiology or Medicine for his w... |
| | | 03/25/08 | Nastech Pharmaceutical Company Inc. to Present RNAi Data| BOTHELL, Wash.--(BUSINESS WIRE)--March 25, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that
Narendra Vaish, Ph.D., MBA, Senior Research Scientist and Group Leader
- RNAi Platform Technologies, will present a poster titled: RNAi
Activity from siRNA Duplexes Containing Nicks or Gaps in the Passenger
Strand, at the Keystone Symposia's RNAi, MicroRNA, and Non-coding RNA
meeting, on Saturday, March 29, 2008.
"We are pleased to have the opportunity to presen... |
| | | 03/21/08 | Nastech Pharmaceutical Company Inc. Complies with Nasdaq Marketplace Rule 4350(b)(1)(B)| BOTHELL, Wash.--(BUSINESS WIRE)--March 21, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK), in compliance with Nasdaq
Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of
receipt of an audit opinion that contains a going concern
qualification, disclosed that our Annual Report (Form 10-K) for the
year ended December 31, 2007 contains a going concern qualification
from our independent registered public accounting firm, KPMG LLP.
This announcement does not... |
| | | 03/17/08 | Nastech Announces Fourth Quarter and Full Year 2007 Financial Results| BOTHELL, Wash.--(BUSINESS WIRE)--March 17, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial
results for the fourth quarter and year ended December 31, 2007.
Revenue for the three months ended December 31, 2007 was $6.4
million, compared to $4.8 million for the quarter ended December 31,
2006. The fourth quarter 2007 period included recognition of
approximately $5.5 million in previously deferred revenue related to
our Parathyroid Hormone (PTH1-34) ... |
| | | 03/13/08 | Nastech Pharmaceutical Company Inc. to Present at the Invest Northwest CEO & Investor Forum| BOTHELL, Wash.--(BUSINESS WIRE)--March 13, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it
will present at the Invest Northwest CEO & Investor Forum on Tuesday,
March 18, 2008, at 4:30 p.m. Pacific Time at the Bell Harbor
International Conference Center in Seattle, Washington.
To access the live audio webcast for this conference, please log
on to Nastech's Web site at http://www.nastech.com approximately 15
minutes prior to the presentation in orde... |
| | | 03/11/08 | Nastech Pharmaceutical Company Inc. Completes Key RNAi Patent Filings| Conference call at 4:15 pm Eastern time (1:15 pm Pacific time)
today
BOTHELL, Wash.--(BUSINESS WIRE)--March 11, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
completed filing 83 patent applications (79 international applications
and 4 U.S. applications) directed toward 144 different genes with
siRNA's designed and modified using Nastech's proprietary RNAi
technologies. These gene targets are disease-validated ... |
| | | 03/07/08 | Nastech Pharmaceutical Company Inc. Announces Scientific Advisory Board for MDRNA, Inc., its Wholly-Owned RNAi Subsidiary| BOTHELL, Wash., Mar 07, 2008 (BUSINESS WIRE) -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today
the appointment of a Scientific Advisory Board (SAB) for MDRNA, Inc.,
its wholly-owned subsidiary for the development of RNAi technology and
therapeutics. The SAB, initially comprised of three noted scientists
and clinicians, will provide critical scientific and medical input on
MDRNA's strategic direction.
"The formation of such a strong Scientific Advisory Board speaks
to o... |
| | | 02/29/08 | Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008| BOTHELL, Wash., Feb 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will host a conference
call with investors and security analysts on Monday, March 3, 2008, at 11:30
a.m. Eastern time (8:30 a.m. Pacific time) to discuss the Company's corporate
restructuring initiatives and future strategy. To participate in the live
conference call, U.S. residents should dial (800) 901-5259 and international
callers sho... |
| | | 02/12/08 | Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring| BOTHELL, Wash., Feb. 12 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its Board of Directors has
approved a plan to further reduce operating expenses and align the company's
workforce with its strategic, business and clinical development requirements.
"The workforce reduction of approximately 50 employees will enable us to
drive our key clinical development and RNAi programs forward in a more
efficient manner for the benefit of ... |
| | | 02/05/08 | Nastech Appoints MDRNA, Inc. Directors Strategic Advisory Board| BOTHELL, Wash., Feb. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that it has named
members to the MDRNA, Inc. ("MDRNA") Directors Strategic Advisory Board that
will provide scientific, financial and corporate governance expertise as
Nastech moves to establish MDRNA, currently a wholly-owned subsidiary, as an
independent company.
Advisory Board appointees include:
Susan B. Bayh, J.D. has been a director of Nastech s... |
| | | 01/08/08 | Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity| BOTHELL, Wash., Jan 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the completion of enrollment for its
Phase 2 clinical trial of PYY3-36 Nasal Spray to treat obesity. The Company
enrolled 551 obese patients at multiple clinical sites in the United States
for a six-month, randomized, placebo-controlled dose ranging study. The study
is designed to evaluate three different doses of PYY3-36 Nasal Spray compared
to placeb... |
| | | 01/08/08 | Nastech Receives Notice of Allowance for U.S. Patent Related to Methods for Identifying Cell-Specific Targeting Peptides| BOTHELL, Wash., Jan 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the U.S. Patent and Trademark
Office (USPTO) has issued a Notice of Allowance for U.S. patent application
No. 10/976,942, entitled "Phage Displayed Trp Cage Ligands." The patent
application has claims that relate to a novel, high-throughput method for
identifying peptides which can bind to specific cell types.
"A major obstacle in the develo... |
| | | 01/07/08 | Nastech Appoints Bruce R. York as Interim Chief Financial Officer| BOTHELL, Wash., Jan. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the appointment of Bruce R. York to the
position of Secretary and interim Chief Financial Officer, effective January
4, 2008. Mr. York will replace Philip C. Ranker, who resigned as Chief
Financial Officer and Secretary of Nastech effective January 4, 2008.
Mr. York has held senior financial positions at a number of biotechnology
and technology companies during his nearly ... |
| | | 12/20/07 | Nastech Announces Promotion of Gordon Brandt, M.D. to President| BOTHELL, Wash., Dec. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has promoted Gordon
Brandt, M.D. to President of Nastech. Dr. Brandt previously held the title of
Executive Vice President, Clinical Research and Medical Affairs. Dr. Steven
Quay will remain the Company's Chairman and Chief Executive Officer.
"We are pleased to promote Gordon to the position of President of Nastech
as he has been instrumental in progressing o... |
| | | 12/18/07 | Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.| Assignment of over 100 RNA-related Inventions
a Key Step in Establishing MDRNA as an Independent Company
BOTHELL, Wash., Dec. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that it has assigned
(i) certain Nastech licenses to third-party intellectual property and (ii)
Nastech's own intellectual property, as such intellectual property relates to
the development of RNA-based therapeutics, to its subsidiary, MD... |
| | | 12/05/07 | Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding| BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that they have entered into a
feasibility study with an undisclosed global leader in the production of
plasma products, to develop an alternative dosage form of Factor IX protein
which is currently administered by injection to control and prevent bleeding
in patients with hemophilia B.
"We look forward to working with our new global partner to evaluate the
feasibilit... |
| | | 11/27/07 | Nastech to Present at BMO Capital Markets Focus on Healthcare Conference| BOTHELL, Wash., Nov. 27 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BMO
Capital Markets Focus on Healthcare Conference on Wednesday, December 5, 2007
at 2:00 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to regi... |
| | | 11/13/07 | Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs| Company to Host Webcast and Conference Call
BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today its corporate
restructuring initiatives aimed at reducing operating expenses and enhancing
shareholder value. Nastech will seek to establish its subsidiary, MDRNA, Inc.,
as an independent, separately financed company as was announced today, and
will concentrate on Phase 2 clinical and partnered programs as... |
| | | 11/13/07 | Nastech to Establish Subsidiary, MDRNA, Inc., as an Independent Company to Focus on the Development of RNA-Based Therapeutics| BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that the Board of
Directors has approved the recommendation of its Special Committee to move
forward with the process of establishing Nastech's wholly-owned subsidiary,
MDRNA, Inc. ("MDRNA"), as an independent company. Nastech is transferring its
intellectual property and agreements related to RNA interference ("RNAi") into
MDRNA. The new structure will give... |
| | | 11/07/07 | Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble| Company Will Advance Product into Phase 2 Bone Mineral Density Study in 1Q08
BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has reacquired the rights
to teriparatide (Parathyroid Hormone; PTH1-34) nasal spray for the treatment
of osteoporosis from its collaboration partner, Procter & Gamble
Pharmaceuticals, Inc. The reacquisition follows notification on Nov. 6, 2007,
of Procter & Gamble's decision to terminat... |
| | | 10/31/07 | Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference| BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Acumen
BioFin Rodman & Renshaw Healthcare Conference on Monday, November 5, 2007 at
2:40 p.m. Eastern Time at the New York Palace Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register ... |
| | | 10/29/07 | Nastech Announces Third Quarter 2007 Financial Results| BOTHELL, Wash., Oct. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the
three- and nine-month periods ended September 30, 2007.
Revenue for the quarter ended September 30, 2007 was $1.9 million,
compared to $5.5 million for the quarter ended September 30, 2006. The 2006
period included revenue of $4.8 million related to our Parathyroid Hormone
(PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuti... |
| | | 10/22/07 | Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007| BOTHELL, Wash., Oct. 22 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its third quarter financial
results will be released on Monday, October 29, 2007. Management will host a
conference call with investors and financial analysts to discuss these results
and to provide an update of the Company's clinical pipeline at 4:30 p.m.
Eastern Time (1:30 p.m. Pacific Time).
To participate in the live conference call, U.S. residents should di... |
| | | 10/05/07 | Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery| BOTHELL, Wash., Oct. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular-biology based drug delivery
technology, announced today the establishment of the Jeffrey Wenig Memorial
Award for Outstanding Achievement in Drug Delivery, and its first recipients,
Dr. Robert S. Langer of the Massachusetts Institute of Technology and Dr. Paul
H. Johnson of Nastech.
"Cutting edge drug delivery technologies are critical to the development
and s... |
| | | 10/04/07 | Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery| BOTHELL, Wash., Oct. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the promotion of Henry "Rick"
Costantino, Ph.D., to Chief Scientific Officer of Delivery. Dr. Costantino
will assume the responsibilities for leading Nastech's development of new drug
delivery technologies for peptide and protein therapeutics. Paul Johnson,
Ph.D., Nastech's Chief Scientific Officer since 2003, is retiring tomorrow,
October 5, 2007, as was previously annou... |
| | | 10/01/07 | Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity| BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint.
The Phase 2 study design will evaluate three different doses of Nastech's PYY3-36 Nasal Spray compared to placebo ... |
| | | 09/26/07 | Nastech to Host 2007 Analyst and Institutional Investor Day| BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional
investor day in New York City on Thursday, October 4, 2007 from 12:00 p.m. -
3:00 p.m. Eastern Time at the Westin New York at Times Square, on 270 West
43rd Street. The luncheon event will feature a presentation from Steven C.
Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer and Gordon
Brandt, M.D., Executive Vice President... |
| | | 09/26/07 | Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes| - Rapid-Acting, Non-Invasive Nasal Spray Dosage form is Patient Friendly and
Avoids Potential Safety Concerns of Pulmonary Delivery -
BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the start of a Phase 2 clinical
trial evaluating the Company's rapid-acting Insulin Nasal Spray in
approximately 20 patients with type 2 diabetes. The study is a randomized,
crossover study evaluating formulations of Insulin ... |
| | | 09/20/07 | Nastech to Present at UBS Global Life Sciences Conference| BOTHELL, Wash., Sept. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the UBS
Global Life Sciences Conference on Wednesday, September 26, 2007 at 12:00 p.m.
Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any nec... |
| | | 08/08/07 | Nastech Announces Second Quarter 2007 Financial Results| BOTHELL, Wash., Aug. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the three-
and six-month periods ended June 30, 2007.
Revenue for the three months ended June 30, 2007 was $4.9 million,
compared to $11.4 million for the three months ended June 30, 2006. The 2006
period included revenue of $10.8 million related to our Parathyroid Hormone
(PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuticals,... |
| | | 08/06/07 | Nastech Pharmaceutical Company to Host Webinar on its Strategy for Development of RNAi Therapeutics for Treatment of Influenza| Presented by Steven Quay, M.D., Ph.D., Chairman, President and CEO of Nastech,
and Michael Templin, Ph.D., Director of Pharmacology and Toxicology
BOTHELL, Wash., Aug. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will host a Webinar to discuss the Company's novel
approach for the development of small interfering RNA (siRNA) therapeutics for
treatment of influenza. Details follow:
What: Webinar discussing the approach of using siRNAs that ta... |
| | | 08/01/07 | Nastech to Release Second Quarter Financial Results and Host Webcast on Wednesday, August 8, 2007| BOTHELL, Wash., Aug. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its second quarter financial
results will be released on Wednesday, August 8, 2007 after the Nasdaq Global
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update of
the Company's clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the... |
| | | 07/17/07 | Nastech Pharmaceutical Company Announces Issuance of Patents for Parathyroid Hormone Nasal Spray for Osteoporosis and PYY Nasal Spray for Obesity| BOTHELL, Wash., July 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of two U.S. patents
by the U.S. Patent and Trademark Office. The patents relate to the Company's
Parathyroid Hormone Nasal Spray for treatment of osteoporosis, No. 7,244,709,
titled "Compositions and Methods for Enhanced Mucosal Delivery of Parathyroid
Hormone," and PYY Nasal Spray for treatment of obesity, No. 7,244,412, titled
"Methods for Manipulating Upp... |
| | | 06/12/07 | Nastech Announces Issuance of a U.S. Patent for Nascobal(R) Nasal Spray| Triggers $2 Million Milestone Payment from QOL Medical
BOTHELL, Wash., June 12 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of a U.S. patent, No.
7,229,636, from the U.S. Patent and Trademark Office, titled "Cyanocobalamin
Low Viscosity Aqueous Formulations for Intranasal Delivery." Issuance of this
patent triggers an obligation by QOL Medical LLC to pay Nastech a $2 million
milestone under the license agreement g... |
| | | 06/07/07 | Nastech to Present at Needham & Company Biotechnology & Medical Technology Conference| BOTHELL, Wash., June 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the
Needham & Company Biotechnology & Medical Technology Conference on Thursday,
June 14, 2007 at 8:30 a.m. Eastern Time at the New York Palace Hotel in New
York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the pr... |
| | | 05/25/07 | Nastech to Present at Friedman Billings Ramsey Growth Conference| BOTHELL, Wash., May 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the
Friedman Billings Ramsey Growth Conference on Wednesday, May 30, 2007 at 11:15
a.m. Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any nece... |
| | | 05/07/07 | Nastech Announces First Quarter 2007 Financial Results| BOTHELL, Wash., May 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended March 31, 2007.
Revenue for the three months ended March 31, 2007 was $5.0 million,
compared to $6.7 million for the three months ended March 31, 2006. The 2007
period included recognition of reimbursement revenue related to Nastech's
Parathyroid Hormone (PTH 1-34) nasal spray collaboration with Procter & Gamble
Pharmaceuticals,... |
| | | 05/03/07 | Nastech to Present at Acumen BioFin Rodman & Renshaw Global Healthcare Conference|
UPDATE: NASTECH WILL NOT BE PRESENTING AT THIS CONFERENCE
BOTHELL, Wash., May 3 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Acumen
BioFin Rodman & Renshaw Global Healthcare Conference on Monday, May 14, 2007
at 9:25 a.m. Central European Summer Time (3:25 a.m. Eastern Daylight Time) at
the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
To access the live audio webcast for this conference, pl... |
| | | 05/01/07 | Nastech to Present at UBS Global Generic and Specialty Pharmaceuticals Conference| BOTHELL, Wash., May 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the UBS
Global Generic and Specialty Pharmaceuticals Conference on Wednesday, May 9,
2007 at 10:00 a.m. Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and do... |
| | | 04/26/07 | Nastech to Release First Quarter Financial Results and Host Webcast on Monday, May 7, 2007| BOTHELL, Wash., April 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial
results will be released on Monday, May 7, 2007 after the Nasdaq National
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update of
the Company's clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the l... |
| | | 03/16/07 | Nastech to Present at Invest Northwest Investor and CEO Forum| BOTHELL, Wash., March 16 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Invest
Northwest Investor and CEO Forum on Tuesday, March 20, 2007 at 4:35 p.m.
Pacific Time at the Bell Harbor International Conference Center in Seattle.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to regi... |
| | | 03/07/07 | Nastech Announces Fourth Quarter and Full Year 2006 Financial Results| BOTHELL, Wash., March 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), today reported financial results for the fourth
quarter and year ended December 31, 2006.
Revenue for the three months ended December 31, 2006 was $4.8 million,
compared to revenue of $1.3 million for the 2005 period. Revenue for the year
ended December 31, 2006 was $28.5 million, compared to $7.4 million for the
2005 period. The increase in revenue for the full year was due to inc... |
| | | 02/23/07 | Nastech to Release Fourth Quarter and Full Year 2006 Financial Results and Host Webcast on Wednesday, March 7, 2007| BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its fourth quarter and full
year 2006 financial results will be released on Wednesday, March 7, 2007 after
the Nasdaq National Market System closes. Management will host a conference
call with investors and financial analysts to discuss these results and to
provide an update of the Company's clinical pipeline at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time).
... |
| | | 02/07/07 | Nastech to Present at BIO CEO & Investor Conference| BOTHELL, Wash., Feb. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BIO
CEO & Investor Conference on Tuesday, February 13, 2007 at 12:00 p.m. Eastern
Time at The Waldorf-Astoria Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any nece... |
| | | 01/18/07 | Nastech Announces Pricing of Common Stock Offering| BOTHELL, Wash., Jan. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the pricing of an underwritten
public offering of 3.25 million shares of its common stock at an estimated
total public offering price of up to approximately $42.9 million. The
offering is being made pursuant to a shelf registration that became effective
on November 29, 2006. All of the shares are being sold by Nastech. UBS
Investment Bank acted as sole bookrunner for... |
| | | 12/21/06 | Nastech Reports Positive PYY Nasal Spray Clinical Trial Data and Will Advance Obesity Clinical Program in 2007| Trial Demonstrates Both Intravenous and PYY Nasal Spray
Produce Satiety and Calorie Reduction
BOTHELL, Wash., Dec. 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported positive results from a dose
ranging study designed to evaluate the pharmacokinetic parameters, appetite,
food intake and safety of various doses of Nastech's proprietary PYY(3-36)
nasal spray in obese subjects. The study identified doses for a long... |
| | | 12/06/06 | Nastech Announces Positive Phase 1 Clinical Results of Insulin Nasal Spray Compared to Exubera(R) Inhalation Powder and NovoLog(C) Insulin Aspart Injection| Study shows Insulin Nasal Spray provides the fastest insulin response which
may be especially useful for type 2 diabetic patients
BOTHELL, Wash., Dec. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced results from a placebo controlled,
dose-escalation, cross-over Phase 1 study of Nastech's proprietary insulin
nasal spray formulations, NovoLog insulin aspart (rDNA origin) injection and
Exubera (insulin human [rDNA origin]) Inhala... |
| | | 12/04/06 | Nastech Pharmaceutical Company Inc. Provides Update on Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today provided a progress report on the
significant clinical development program currently being conducted and planned
for the Parathyroid Hormone (PTH1-34) Nasal Spray, which is under development
for the treatment of osteoporosis. Nastech also provided information with
regard to an amendment to the contract with Procter & Gamble Pharmaceuticals,
Inc., a division of The Procter &... |
| | | 12/04/06 | Nastech to Present at BMO Capital Markets Focus on Healthcare Conference| BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BMO
Capital Markets Focus on Healthcare Conference on Wednesday, December 6, 2006
at 1:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to reg... |
| | | 11/08/06 | Nastech RNAi Webinar Scheduled for Thursday, November 9, 2006, at 10:30 a.m. Eastern Time| Emerging RNAi Therapeutics Programs and Delivery Technology to be
Presented by Steven C. Quay, M.D., Ph.D., Chairman, President and CEO
BOTHELL, Wash., Nov. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting a Webinar to discuss the science
of RNA interference (RNAi), its emerging siRNA therapeutics programs and siRNA
drug delivery technology. Details follow:
What: Webinar on the science of RNAi and the Company's RNAi ... |
| | | 11/08/06 | Nastech Licenses RNAi Intellectual Property and Technology from City of Hope| Novel Dicer-Substrate RNAi Technology Could Offer Increased Potency
for Drug Development as Compared to Conventional RNAi Technology
BOTHELL, Wash. and DUARTE, Calif., Nov. 8 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
entered into a license agreement with City of Hope for rights to Dicer-
Substrate RNA interference (RNAi) intellectual property and technology.
Nastech obtained exclusive rights to five undisclo... |
| | | 11/02/06 | Nastech Announces Presentation of Scientific Abstracts at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting| Study Demonstrating that Nastech's Calcitonin-Salmon Nasal Spray is
Bioequivalent to Novartis' Miacalcin(R) (Calcitonin-Salmon) Nasal Spray and
Nastech's Insulin Nasal Spray Formulation Screening Results Presented
BOTHELL, Wash., Nov. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the presentation of two abstracts this
week at the American Association of Pharmaceutical Scientists Annual Meeting
in San Antonio, Texas. The abstrac... |
| | | 11/01/06 | Nastech Announces Third Quarter 2006 Financial Results| BOTHELL, Wash., Nov. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the three-
and nine-month periods ended September 30, 2006.
Revenue for the three months ended September 30, 2006 was $5.5 million,
compared to $1.2 million for the prior year period. Revenue for the nine
months ended September 30, 2006 was $23.7 million, compared to $6.2 million
for the prior year period. Revenue for 2006 includes approximate... |
| | | 10/31/06 | Nastech Pharmaceutical Company Inc. to Host Webinar on Its Emerging RNAi Therapeutics Programs and siRNA Delivery Technology| - Steven C. Quay, M.D., Ph.D., Chairman, President and CEO, to Present on
Thursday, November 9, 2006 -
BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will host a Webinar
concerning its emerging siRNA therapeutics programs and siRNA drug delivery
technology. Steven C. Quay, M.D., Ph.D., Chairman, President and CEO will
present at the event.
What: RNAi webinar on the science a... |
| | | 10/30/06 | Nastech to Present at Rodman & Renshaw Healthcare Conference| BOTHELL, Wash., Oct. 30 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Rodman
& Renshaw Healthcare Conference on Tuesday, November 7, 2006 at 12:45 p.m.
Eastern Time at the New York Palace Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and do... |
| | | 10/25/06 | Nastech to Release Third Quarter Financial Results and Host Webcast on Wednesday, November 1, 2006| BOTHELL, Wash., Oct. 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its third quarter financial
results will be released on Wednesday, November 1, 2006 after the Nasdaq
National Market System closes. Management will host a conference call with
investors and financial analysts to discuss these results and to provide an
update to its clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the liv... |
| | | 10/19/06 | Nastech Files Shelf Registration Statement| BOTHELL, Wash., Oct. 19 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has filed a shelf
registration statement on Form S-3 with the U.S. Securities and Exchange
Commission (SEC), pursuant to which Nastech may issue common stock from time
to time, up to an aggregate of $125 million. While the Company has no current
plans to access the capital markets, the shelf registration statement, once
declared effective by the SEC, would allow ... |
| | | 09/29/06 | Nastech Provides Calcitonin Salmon Nasal Spray Complete Response to FDA| In Vitro Testing Demonstrated no Evidence of Calcitonin-Preservative
Interaction or Calcitonin Aggregation Differences Due to Preservatives
BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today it has submitted a complete
response to the FDA's Office of Generic Drugs regarding the potential for
immunogenicity that might result from a possible interaction between
calcitonin-salmon and chlorobutanol, the preserv... |
| | | 09/29/06 | Nastech Pharmaceutical Named One of the Pacific Northwest's Fastest Growing Life Sciences Companies in Deloitte's Technology Fast 50 Program| BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) has been named to Deloitte's prestigious
Technology Fast 50 Program for the Pacific Northwest, a ranking of the 50
fastest growing technology, media, telecommunications and life sciences
companies in Washington, Oregon and Idaho by Deloitte & Touche USA LLP, one of
the nation's leading professional services organizations. Rankings are based
on the percentage revenue growth during ... |
| | | 09/26/06 | Nastech Receives $1.9 Million National Institute of Health-R01 Grant for Development of RNAi Therapeutics to Prevent and Treat Influenza| BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the National Institute of
Allergy and Infectious Diseases (NIAID), a division of the National Institutes
of Health (NIH), awarded the Company a $1.9 million Research Project (R01)
grant. This award combined with an earlier SBIR Phase 1 Small Business
Innovation Research (SBIR) grant award brings total program funding to
approximately $2.3 million from the NIH that ... |
| | | 09/26/06 | Nastech to Host 2006 Analyst and Institutional Investor Day| BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional
investor day in New York City on Wednesday, October 4, 2006 from
12:00 p.m. -- 3:00 p.m. Eastern Time at the InterContinental The Barclay New
York, on 111 East 48th Street. The event will feature presentations from
Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer
of Nastech, and Paul H. Johnson, Ph.D., Senior Vice... |
| | | 09/21/06 | Nastech to Present at UBS Global Life Sciences Conference| BOTHELL, Wash., Sept. 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the UBS
Global Life Sciences Conference on Tuesday, September 26, 2006 at 8:30 a.m.
Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any necess... |
| | | 09/19/06 | Nastech Initiates Clinical Development of Rapid Acting Insulin Nasal Spray for Diabetes| - Phase I pharmacokinetic study to compare Nastech's intranasal insulin to injectable insulin and Exubera(R) (insulin human [rDNA origin]) Inhalation Powder -BOTHELL, Wash., Sept 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the initiation of a Phase I
pharmacokinetic study designed to evaluate the safety, bioavailability and
glucose response of Nastech's proprietary, rapid acting intranasal insulin
formulation. ... |
| | | 08/29/06 | Nastech Awarded Development Grant for RNAi Therapeutics to Prevent and Treat Influenza| Funding provided by the National Institutes of Health
BOTHELL, Wash., Aug. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the National Institute of
Allergy and Infectious Diseases (NIAID), a division of the National Institutes
of Health (NIH), awarded the company a Phase 1 Small Business Innovation
Research (SBIR) grant. This award will be used to further develop the
Company's small-interfering RNA (siRNA) therapeutics t... |
| | | 08/14/06 | Nastech Initiates Dose Ranging Study of PYY(3-36) Nasal Spray for Obesity| BOTHELL, Wash., Aug. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the initiation of a dose ranging
study designed to evaluate the pharmacokinetic parameters, appetite, food
intake and safety of various doses of Nastech's proprietary PYY(3-36) nasal
spray in obese subjects. The objective of the study is to identify a dose or
doses which would be appropriate for further study in a long-term Phase II
efficacy and safety clinical trial.
... |
| | | 08/02/06 | Nastech Announces Second Quarter 2006 Financial Results| Quarterly revenue increased more than 600% over prior year to $11.4 million,
Cash and investments increased to $63.3 million
BOTHELL, Wash., Aug. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the three-
and six-month periods ended June 30, 2006.
Revenue for the three months ended June 30, 2006 was $11.4 million,
compared to $1.6 million for the three months ended June 30, 2005. Revenue
for the s... |
| | | 07/25/06 | Nastech Announces the Issuance of a Key Patent Directed to Using PYY by Any Administration Route to Treat Obesity| BOTHELL, Wash., July 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of a patent from the
United States Patent and Trademark Office relating to treatment of obesity
through the use of Peptide YY (PYY), a naturally produced hormone associated
with the modulation of appetite in the brain. The Company is developing a
proprietary PYY nasal spray to treat obesity. U.S. Patent No. 7,081,239
titled "Methods for manipulating upper ... |
| | | 07/24/06 | Nastech to Release Second Quarter Financial Results and Host Webcast on Wednesday, August 2, 2006| BOTHELL, Wash., July 24 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its second quarter financial
results will be released on Wednesday, August 2, 2006 after the Nasdaq
National Market System closes. Management will host a conference call with
investors and financial analysts to discuss these results and to provide an
update to its clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the live c... |
| | | 07/13/06 | Nastech Pharmaceutical Company Receives FDA Communication Concerning Calcitonin-Salmon Nasal Spray| BOTHELL, Wash., July 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that written notification from the
FDA was received on July 10, 2006 stating that Nastech's abbreviated new drug
application (ANDA) for intranasal calcitonin-salmon is not approvable at this
time. In a subsequent conference call on July 11, 2006, Nastech reviewed the
status of the ANDA with the FDA. The FDA expressed a concern relating to the
potential for immunogenici... |
| | | 06/27/06 | Nastech Scientific Abstracts Presented at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference| BOTHELL, Wash., June 27 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) presented two abstracts last week at the American
Association of Pharmaceutical Scientists National Biotechnology Conference in
Boston, Massachusetts.
The abstracts presented included:
*Development of a Glucagon-Like Peptide (GLP)-1 Intranasal Formulation
In vitro and in vivo results with a proprietary intranasal formulation of
GLP-1 were presented. GLP-1 is an incretin hor... |
| | | 06/26/06 | Nastech's Parathyroid Hormone (PTH1-34) Nasal Spray Demonstrated Similar Exposure Levels to Approved Injectable Product in Phase I Study in the Elderly| BOTHELL, Wash., June 26 /PRNewswire-FirstCall/ -- In a preliminary Phase I
clinical trial, a nasal spray dosage form of Parathyroid Hormone (PTH1-34)
developed by Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) provided
comparable exposure levels to the approved subcutaneous product, Forteo(R)
(teriparatide), in elderly subjects, according to data presented at ENDO(R)
2006, the 88th Annual Meeting of the Endocrine Society. If further development
is successful and leads to regulatory... |
| | | 06/26/06 | Nastech Pharmaceutical Company Inc. Enters into Development and License Agreement With Amylin Pharmaceuticals, Inc.| BOTHELL, Wash., June 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today an agreement with Amylin
Pharmaceuticals, Inc. to develop a nasal spray formulation of exenatide.
Preclinical studies of the formulation have been completed in preparation for
initiating studies to determine feasibility in human subjects.
Under terms of the agreement, Nastech will receive milestone payments and
royalties on product sales. If ... |
| | | 06/08/06 | Nastech Receives $7 Million Milestone Payment from Procter & Gamble for Advancement of Parathyroid Hormone (PTH1-34) Nasal Spray Program| BOTHELL, Wash., June 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the receipt of a $7 million
payment for attaining a development milestone under the Company's
collaboration with Procter & Gamble Pharmaceuticals, Inc., a division of The
Procter & Gamble Company (NYSE: PG), for development and commercialization of
Parathyroid Hormone (PTH1-34) nasal spray for treatment of osteoporosis. The
milestone will be recognized as revenue in the q... |
| | | 06/07/06 | Nastech Submits Investigational New Drug Application for PYY3-36 Nasal Spray to Treat Obesity| BOTHELL, Wash., June 7, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the submission of an
Investigational New Drug (IND) application to the U.S. Food and Drug
Administration for PYY3-36 (PYY) nasal spray, the company's lead
investigational product candidate for treatment of obesity. The filing of the
IND precedes the initiation of clinical studies in the United States.
The study included in the IND is designed t... |
| | | 06/06/06 | Nastech Enters Into Supply Agreement with Procter & Gamble for Parathyroid Hormone (PTH1-34) Nasal Spray| BOTHELL, Wash., June 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today an agreement with Procter & Gamble
Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG),
to manufacture and supply PTH1-34 nasal spray for the potential
commercialization of this investigational product for the treatment of
osteoporosis. This agreement further strengthens the collaboration between
the companies that began with the development and ... |
| | | 06/05/06 | Nastech to Present at Needham & Company Biotechnology and Medical Technology Conference| BOTHELL, Wash., June 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Needham & Company
Biotechnology and Medical Technology Conference on Wednesday, June 14, 2006 at
9:30 a.m. Eastern Time at The New York Palace Hotel in New York City. Steven
C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech, will provide a
corporate overview, including a review of the Company's product development
programs.
To access the live aud... |
| | | 05/25/06 | Nastech to Present at Friedman Billings Ramsey Growth Investor Conference| BOTHELL, Wash., May 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Friedman Billings Ramsey
Growth Investor Conference on Wednesday, May 31, 2006 at 11:15 a.m. Eastern
Time at the Grand Hyatt in New York City. Tim Duffy, Executive Vice President,
Marketing and Business Development of Nastech, will provide a corporate
overview, including a review of the Company's product development programs.
To access the live audio webcast... |
| | | 05/03/06 | Nastech Announces First Quarter 2006 Financial Results| BOTHELL, Wash., May 3 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended March 31, 2006.
Revenue for the three months ended March 31, 2006 was $6.7 million,
compared to $3.3 million for the three months ended March 31, 2005. The 2006
period included recognition of approximately $3.7 million in previously
deferred revenue related to our Merck collaboration that was terminated on
March 1, 2006, reimbur... |
| | | 04/28/06 | Pharmacokinetic Data for Nastech's Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile to Approved Injectable Product| BOTHELL, Wash., April 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) presents data today from a Phase I pharmacokinetic
study of Parathyroid Hormone (PTH1-34) nasal spray demonstrating a similar
pharmacokinetic profile to the approved subcutaneous product, Forteo(R)
(teriparatide). The data are being presented at the American Association of
Clinical Endocrinologists Annual Meeting in Chicago.
The Phase I study was conducted ... |
| | | 04/24/06 | Nastech to Release First Quarter Financial Results and Host Webcast on Wednesday, May 3, 2006| BOTHELL, Wash., April 24 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial
results will be released on Wednesday, May 3, 2006, after the Nasdaq National
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update on
the Company's clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in th... |
| | | 04/18/06 | Nastech to Present at UBS Global Specialty Pharmaceuticals Conference| BOTHELL, Wash., April 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the UBS Global Specialty
Pharmaceuticals Conference on Tuesday, April 25, 2006, at 1:00 p.m. Eastern
Time at The Grand Hyatt in New York City. Steven C. Quay, M.D., Ph.D.,
Chairman, President and CEO of Nastech, will provide a corporate overview,
including a review of the Company's product development programs.
To access the live audio webcast for this confer... |
| | | 03/16/06 | Nastech Presents Successful In Vitro and In Vivo Results with Its RNAi Therapeutics Program for Influenza| BOTHELL, Wash., March 16 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
the presentation of results demonstrating the effectiveness of the Company's
small interfering RNA (siRNA) therapeutics to broadly target and inhibit
influenza viral production at the 8th International Symposium on Respiratory
Viral Infections Conference.
In vitr... |
| | | 03/15/06 | Nastech Announces Fourth Quarter and Full Year 2005 Financial Results| BOTHELL, Wash., March 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, today reported
financial results for the fourth quarter and year ended December 31, 2005.
Revenue for the three months ended December 31, 2005 was $1.3 million,
compared to revenue of $1.5 million for the 2004 period. Revenue for the year
ended December 31, 2005 was $7.4 million,... |
| | | 03/15/06 | Nastech Pharmaceutical Company Inc. Announces Multi-Compound Agreement With Novo Nordisk A/S| BOTHELL, Wash., March 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that it has entered into a multi-compound, feasibility study agreement with
Novo Nordisk A/S (NYSE: NVO) with respect to certain Novo Nordisk therapeutic
compounds. Specific compounds and indications were not announced. Financial
and other terms were not disclosed.
... |
| | | 03/09/06 | Nastech to Release Fourth Quarter and Full Year 2005 Financial Results and Host Webcast on Thursday, March 16, 2006| BOTHELL, Wash., March 9 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that its fourth quarter and full year 2005 financial results will be released
on Thursday, March 16, 2006 after the Nasdaq National Market System closes.
Management will host a conference call with investors and financial analysts
to discuss these results and to provid... |
| | | 03/02/06 | Nastech Pharmaceutical Company Reschedules Conference Call to Discuss Reacquisition of PYY3-36 for the Treatment of Obesity From Merck| Conference Call to be Held at 8:30 a.m. Eastern Time on Friday, March 3, 2006
BOTHELL, Wash., March 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
that it will hold a conference call on Friday, March 3, 2006, at 8:30 a.m.
Eastern Time to discuss its reacquisition of PYY3-36 for the treatment of
obesity from Merck & Co., Inc.
Confer... |
| | | 03/02/06 | Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray for Treatment of Obesity and Will Advance Its Clinical Development| Mar 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
that it has reacquired its rights to PYY3-36 (PYY) nasal spray for treatment
of obesity from its collaboration partner, Merck & Co., Inc.
Nastech's agreement with Merck has terminated with receipt of Merck's
notice effective March 1, 2006. Merck's conclusio... |
| | | 02/28/06 | Nastech's Facility Approved for Commercial Manufacturing of Calcitonin-Salmon Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash., Feb. 28 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
the successful completion of the FDA's Pre-Approval Inspection (PAI) of its
Bothell, Washington facility. Successful completion of this PAI enables
Nastech to manufacture calcitonin-salmon nasal spray for commercial use upon
FDA approval of the Company's ANDA (Abbrevia... |
| | | 02/23/06 | Nastech to Present at Citigroup Healthcare Conference| BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, will be
presenting at the Citigroup Healthcare Conference on Monday, February 27, 2006
at 3:40 p.m. Eastern Time at The Mayflower Hotel in Washington, D.C. Gordon
Brandt, M.D., Executive V.P., Clinical Research and Medical Affairs of
Nastech, will provide a corporate overview, includi... |
| | | 02/23/06 | Nastech Acquires RNAi Therapeutics Program Targeting Influenza from Galenea| Exclusive Rights to Leading Technology and Intellectual Property to Develop
RNAi Therapeutics for Influenza and Respiratory Diseases
BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
the expansion of its RNAi therapeutics pipeline by initiating an RNAi
therapeutics program targeting influenza and respirato... |
| | | 02/07/06 | Nastech to Present at BIO CEO & Investor Conference| BOTHELL, Wash., Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, will be
presenting at the BIO CEO & Investor Conference on Wednesday, February 15,
2006, at 11:30 a.m. Eastern Time, at The Waldorf Astoria in New York City.
Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech, will
provide a corporate overview... |
| | | 02/01/06 | Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash. and CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in developing
therapeutics using advanced drug delivery technologies, and Procter & Gamble
Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG),
announced today a collaboration to develop and commercialize Nastech's
Parathyroid Hormone (PTH1-34) nasal spray for the treatment of osteoporosis.
Clinical and non-clinical studies on PTH1-34 nas... |
| | | 01/03/06 | Nastech Pharmaceutical Company Names Philip Ranker Chief Financial Officer| BOTHELL, Wash., Jan. 3 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
products and technologies, today announced today that Philip Ranker has been
named Chief Financial Officer and Corporate Secretary. Mr. Ranker has served
as Nastech's interim Chief Financial Officer and Corporate Secretary since
September 2005 and has been an integral part of Nastech's financial
organization and growth in his previous r... |
| | | 12/14/05 | Nastech Presents New Methods for Peptide and Protein Drug Delivery at The American Society for Cell Biology Annual Meeting| Research Supports a Role for Endothelial Tight Junctions in Atherosclerosis
and Suggests New Therapeutic Targets for Cardiovascular Disease
BOTHELL, Wash., Dec. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, today announced
the presentation of data from the Company's transmucosal peptide and protein
drug delivery program at The American Society for C... |
| | | 11/17/05 | Nastech Presents Positive Results on RNA Interference Program for Treatment of Rheumatoid Arthritis at the American College of Rheumatology Annual Scientific Meeting| BOTHELL, Wash., Nov. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced the
presentation of data from its RNA interference (RNAi) therapeutic program for
rheumatoid arthritis at the American College of Rheumatology Annual Scientific
Meeting.
The presentation titled "Development of siRNAs Targeting Human Tumor
Necrosis Factor Alpha (TNF-alph... |
| | | 11/14/05 | Nastech Added to NASDAQ Biotechnology Index| BOTHELL, Wash., Nov. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that it has been selected for addition to the NASDAQ Biotechnology Index(R)
(Nasdaq: NBI) effective Monday, November 21, 2005. All securities in the Index
are listed on the NASDAQ National Market and must meet certain eligibility
criteria, including market value, avera... |
| | | 11/07/05 | Nastech to Present at CIBC World Markets Healthcare Conference| BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics that utilize
proprietary molecular biology-based drug delivery technologies, will be
presenting at the CIBC World Markets Healthcare Conference on Wednesday,
November 9, 2005 at 3:00 p.m. Eastern Time at the Waldorf-Astoria in New York
City. Gordon Brandt, M.D., Executive Vice President, Clinical Research and
Medical Affairs of Nastech, will provide ... |
| | | 11/02/05 | Nastech Announces Third Quarter 2005 Financial Results| BOTHELL, Wash., Nov. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, today reported
financial results for the three- and nine-month periods ended September 30,
2005.
Revenue for the three months ended September 30, 2005 was $1.2 million,
compared to revenue of $0.2 million for the three months ended September 30,
2004. Revenue for the first nine m... |
| | | 10/25/05 | Nastech to Release Third Quarter Financial Results and Host Webcast on Wednesday, November 2, 2005| BOTHELL, Wash., Oct. 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that its third quarter financial results will be released on Wednesday,
November 2, 2005 after the Nasdaq National Market System closes. Management
will host a conference call with investors and financial analysts to discuss
these results and to provide an update to it... |
| | | 10/17/05 | Nastech to Manufacture Nascobal(R) Nasal Spray for QOL Medical| BOTHELL, Wash., Oct. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that, following QOL Medical LLC's acquisition of Nascobal(R) (Cyanocobalamin,
USP) Nasal Spray for the treatment of vitamin B-12 deficiency from Questcor
Pharmaceuticals, Inc. (Amex: QSC), Nastech will be the exclusive manufacturer
of the product for QOL Medical.
... |
| | | 10/17/05 | Nastech Initiates Development Program for Rapid-Acting Intranasal Insulin for Treatment of Diabetes| BOTHELL, Wash., Oct. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announces today
the initiation of a development program for a proprietary intranasal
formulation of rapid-acting insulin.
The formulation is being developed using Nastech's formulation science
expertise and high-throughput human tissue culture screening process, a
proprietary sys... |
| | | 09/29/05 | Nastech Announces Positive Phase I Pharmacokinetic Study Results of Intranasal Parathyroid Hormone (PTH1-34) for Osteoporosis| BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
positive results from a Phase I pharmacokinetic study of intranasal
Parathyroid Hormone (PTH1-34). The objectives of the study were to determine
the nasal absorption and safety of Nastech's PTH1-34 nasal spray versus the
approved subcutaneous product, Forteo(R) (teri... |
| | | 09/27/05 | Nastech to Present at UBS Global Life Sciences Conference| BOTHELL, Wash., Sept 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics that utilize
proprietary molecular biology-based drug delivery technologies, will be
presenting at the UBS Global Life Sciences Conference on Thursday, September
29, 2005 at 11:30 a.m. Eastern Time at the Grand Hyatt New York in New York
City. Gordon Brandt, M.D., Executive Vice President, Clinical Research and
Medical Affa... |
| | | 09/20/05 | Nastech Announces Publication Demonstrating Lower Weight in Preclinical Model Following PYY3-36 Administration| BOTHELL, Wash., Sept. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics that utilize
proprietary molecular biology-based drug delivery technologies, today
announced the publication of preclinical results relating to the
administration of PYY in the International Journal of Obesity.
The peer-reviewed paper, titled "Lower mean weight after 14 days
intravenous administration peptide YY3-36 (PYY3-36) in rabbits," appear... |
| | | 09/15/05 | Nastech to Present at Merriman Curhan Ford & Co. Investor Summit and at the Northwest Medical Device and Biotechnology Investor Forum| BOTHELL, Wash., Sept. 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, will be presenting at two conferences on Tuesday, September 20,
2005. Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive
Officer of Nastech, will be presenting at the Merriman Curhan Ford & Co.
Investor Summit at 11:15 a.m. Pacific Time at the InterContinental Mark
Hopkins Hotel in San Francisco. Gordon Bran... |
| | | 09/08/05 | Nastech Pharmaceutical Company Announces Management Change| BOTHELL, Wash., Sept. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
products and technologies, today announced that Gregory Weaver, Chief
Financial Officer, has resigned to pursue other opportunities. Philip Ranker,
currently Vice President of Finance for Nastech, will serve as interim Chief
Financial Officer and Corporate Secretary, effective immediately.
"We thank Greg for his commitment and valuab... |
| | | 08/25/05 | Nastech Announces Pricing of Common Stock Offering| BOTHELL, Wash., Aug. 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the pricing of an underwritten
public offering of 1,725,000 shares of its common stock at a price of $13.50
per share. The gross proceeds of the offering are expected to be
approximately $23.3 million before deducting underwriting discounts and
commission and offering expenses. The offering is being made from a shelf
registration statement that became effective on October ... |
| | | 08/05/05 | Nastech Withdraws Public Offering of Common Stock| BOTHELL, Wash., Aug 05, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has withdrawn its
previously announced public offering of 1.5 million shares of common stock
under its shelf registration statement.
"We appreciate the interest shown by the investment community in Nastech
as we continue to make progress in our research and clinical programs," said
Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastec... |
| | | 08/01/05 | Nastech Announces Proposed Public Offering of Common Stock| BOTHELL, Wash., Aug. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today plans to offer
1.5 million shares of common stock in an underwritten public offering pursuant
to an effective shelf registration statement. Nastech intends to grant the
underwriters an option to purchase an additional 225,000 shares of common
stock to cover over-allotments.
Needham & Company, LLC is acting as sole lead book-running manager for the
proposed... |
| | | 08/01/05 | Nastech Announces Second Quarter 2005 Financial Results| BOTHELL, Wash., Aug. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, today reported financial results for the three- and six-month
periods ended June 30, 2005.
Revenue for the three months ended June 30, 2005 was $1.6 million,
compared to revenue of $45,000 for the three months ended June 30, 2004.
Revenue for the first six months of 2005 was $4.9 million, compared to
$193,000 in the firs... |
| | | 07/25/05 | Nastech to Release Second Quarter Financial Results and Host Webcast on Monday, August 1, 2005| BOTHELL, Wash., July 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, announced today that its second quarter financial results will
be released on Monday, August 1, 2005 after the Nasdaq National Market System
closes. Management will host a conference call with investors and financial
analysts to discuss these results and to provide an update to its clinical
pipeline at 4:30 p.m. Eastern Time (... |
| | | 07/20/05 | Alnylam Grants Nastech a License to Develop RNAi Therapeutics Against TNF-alpha| License For RNAi Intellectual Property Granted Under Alnylam InterfeRx(TM)
Program
CAMBRIDGE, Mass. and BOTHELL, Wash., July 20 /PRNewswire-FirstCall/ --
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has granted Nastech Pharmaceutical Company
Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, an exclusive InterfeRx(TM) license to discover, develop, and
co... |
| | | 07/07/05 | Nastech CEO Announces Plan To Exercise Expiring Options| BOTHELL, Wash., July 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported that Dr. Steven C. Quay, Chairman,
President and Chief Executive Officer, has filed a Form 144 with the SEC
stating his intention to exercise and hold or sell Nastech stock options
scheduled to expire in August 2005. Dr. Quay intends to use any proceeds from
this transaction to satisfy personal family obligations as well as the
consideration due to Nastech arising from the sto... |
| | | 07/05/05 | Nastech Initiates Phase 1 Clinical Trial for Intranasal Parathyroid Hormone (PTH1-34)| BOTHELL, Wash., July 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, today announced that the Company has commenced a Phase 1
pharmacokinetic study with its intranasal Parathyroid Hormone (PTH1-34) to
treat osteoporosis. The study will be conducted using the Company's advanced
intranasal formulation that utilizes its Tight Junction drug delivery
technology to enable needle-free delivery of ther... |
| | | 07/01/05 | Nastech Pharmaceutical Company Inc. Added to Russell 3000(R) Index| BOTHELL, Wash., July 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
products and technologies, today announced that the Company has been added to
the Russell 3000(R) Index. The Russell 3000 Index offers investors access to
the broad U.S. equity universe representing the 3,000 largest U.S. companies
based on total market capitalization. The Russell 3000 is constructed to
provide a comprehensive, unbiased, a... |
| | | 06/23/05 | Nastech to Host 2005 Analyst and Institutional Investor Day| BOTHELL, Wash., June 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional
investor day in New York City on Tuesday, June 28, 2005 from 12:00 p.m. - 3:00
p.m. Eastern Time at the University Club, on One West 54th Street in New York
City. The event will feature presentations from Steven C. Quay, M.D., Ph.D.,
Chairman, President, and CEO of Nastech as well as the following leading
scientific experts:
* Dr. Black... |
| | | 06/17/05 | Nastech to Participate in Panel Session at BIO 2005 Annual International Convention to Discuss the Regulatory Environment for Obesity Therapeutics| BOTHELL, Wash., June 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, today announced that Steven C. Quay, M.D., Ph.D., Chairman,
President and Chief Executive Officer of Nastech, will participate in a panel
entitled, "Changing Regulatory Environment for Anti-Obesity Drug Development,"
at the BIO 2005 Annual International Convention taking place in Philadelphia,
PA from June 19 ... |
| | | 06/10/05 | Nastech to Present at Morgan Stanley Small Cap Executive Conference| BOTHELL, Wash., June 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Morgan Stanley Small Cap
Executive Conference on Tuesday, June 14, 2005 at 2:45 p.m. Eastern Time at
The Ritz-Carlton New York, Battery Park in New York City. Gordon Brandt,
M.D., Executive Vice President, Clinical Research and Medical Affairs of
Nastech, will provide a corporate overview, including a review of the
Company's product development pr... |
| | | 06/06/05 | Nastech to Present at Pacific Growth Equities Life Sciences Conference| BOTHELL, Wash., June 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Pacific Growth Equities
Life Sciences Conference on Wednesday, June 8, 2005 at 7:30 a.m. Pacific Time
at the InterContinental Mark Hopkins Hotel in San Francisco, CA. Gordon
Brandt, M.D., Executive Vice President, Clinical Research and Medical Affairs
of Nastech, will provide a corporate overview, including a review of the
Company's product development programs.
... |
| | | 05/31/05 | Nastech Awarded Patent Covering Treatment and Prevention of Breast Cancer| BOTHELL, Wash., May 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that it has been awarded U.S.
patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the
Treatment and Prevention of Breast Cancer and Psychiatric Disorders." The
patent covers methods for the treatment of breast cancer by the administration
of long-acting analogues of the peptide hormone oxytocin. The patent contains
11 claims and the inventor is Steven C. Qua... |
| | | 05/26/05 | Nastech to Present at Friedman Billings Ramsey 9th Annual Growth Conference| BOTHELL, Wash., May 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Friedman Billings Ramsey
9th Annual Growth Conference on Thursday, June 2, 2005 at 11:40 a.m. Eastern
Time at the Millennium Broadway Hotel in New York City. Gordon Brandt, M.D.,
Executive Vice President, Clinical Research and Medical Affairs of Nastech,
will provide a corporate overview, including a review of the Company's product
development programs.
To a... |
| | | 05/26/05 | Nastech Receives Innovative Business Award at the 2005 Eastside Business Awards| BOTHELL, Wash., May 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it was awarded the
"Innovative Business Award" in the 2005 Eastside Business Awards, sponsored by
the Bellevue, Washington Chamber of Commerce. Businesses competing for this
award were evaluated on their demonstration of innovation and creativity in
developing a product or service.
"We are privileged to have been recognized by the Bellevue Chamber of
Commerce with... |
| | | 05/23/05 | Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech, Named a Finalist for Ernst & Young Entrepreneur Of The Year(R) 2005 Award| BOTHELL, Wash., May 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that Steven C. Quay, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Nastech, has been named a
finalist by Ernst & Young LLP for the professional services firm's
Entrepreneur Of The Year(R) 2005 Awards in the Pacific Northwest. Dr. Quay
was selected from 40 nominations in the Pacific Northwest by a panel of
independent judges comprised of area leaders from bu... |
| | | 05/18/05 | Nastech to Present at UBS Global Pharmaceuticals and Needham & Company Fourth Annual Biotechnology Conferences| BOTHELL, Wash., May 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that Steven C. Quay, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Nastech, will be presenting
at the UBS Global Pharmaceuticals Conference, taking place May 23-24 at the
Grand Hyatt in New York, and the Needham & Co. Fourth Annual Biotechnology
Conference, taking place May 25-26 at the New York Palace Hotel in New York.
UBS Global Pharmaceuticals Co... |
| | | 05/09/05 | Nastech Announces First Quarter 2005 Financial Results| BOTHELL, Wash., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended March 31, 2005.
Revenue for the quarter ended March 31, 2005 was $3.3 million, compared to
revenue of $0.1 million for the quarter ended March 31, 2004. The increase in
revenue reflects a $2.0 million milestone payment received upon FDA approval
of Nascobal(R) spray, and growth in the number of revenue generating
co... |
| | | 04/27/05 | Nastech to Release First Quarter Financial Results and Host Webcast on Monday, May 9, 2005| BOTHELL, Wash., April 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial
results will be released on Monday, May 9, 2005 after the Nasdaq National
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update to
its clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
To participate in the ... |
| | | 04/19/05 | Nastech to Present at the 4th Annual Invest Northwest Conference| BOTHELL, Wash., April 19 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the 4th Annual Invest
Northwest conference on Tuesday, April 26, 2005 at 2:20 p.m. Pacific Time
(5:20 p.m. Eastern Time) at the Bell Harbor International Conference Center in
Seattle, WA. Steven C. Quay, M.D., Ph.D., Chairman, President and Chief
Executive Officer of Nastech will provide a corporate overview, including a
review of the Company's product development pr... |
| | | 04/12/05 | Nastech Announces Nomination of Susan B. Bayh, J.D., and Alexander D. Cross, Ph.D., to Its Board of Directors| BOTHELL, Wash., April 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has nominated Susan B.
Bayh, J.D., and Alexander D. Cross, Ph.D., to its board of directors.
Mrs. Bayh currently serves on the board of directors of Curis, Inc., a
therapeutic drug development company, Dendreon Corporation, a therapeutic drug
development company, Dyax Corp., a biopharmaceutical company, Emmis
Communications, a diversified media ... |
| | | 04/05/05 | Nastech Presents Promising In Vivo Research Findings with RNAi-Based Therapeutics for Rheumatoid Arthritis| Data Presented in Late-Breaking Session at ASBMB Meeting
BOTHELL, Wash., April 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the presentation of data
demonstrating the successful preclinical, in vivo use of an RNA interference
(RNAi)-based therapeutic drug directed against the expression of human tumor
necrosis factor alpha (H-TNF-alpha), a protein that is over-expressed in
rheumatoid arthritis and plays an important role in disease pa... |
| | | 04/05/05 | Nastech Announces RNAi Therapeutics-Based Rheumatoid Arthritis Clinical Study Collaboration| BOTHELL, Wash., April 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that it has entered into a
clinical research collaboration with the Mayo Clinic to evaluate Nastech's RNA
interference (RNAi)-based therapeutic formulations in immune cells from
patients with rheumatoid arthritis (RA) for the purpose of selecting a
candidate for preclinical and clinical development. Data demonstrating the
successful preclinical, in vivo use of an RNA interf... |
| | | 03/29/05 | Nastech to Highlight Therapeutic RNA Interference Program for Rheumatoid Arthritis, and Tight Junction and Phage Display Research Programs at 2005 American Society of Biochemistry and Molecular Biology Annual Meeting| BOTHELL, Wash., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that data from its therapeutic RNA
interference program for rheumatoid arthritis and tight junction technology
and phage display research programs will be presented during the 2005 American
Society for Biochemistry and Molecular Biology Annual Meeting to be held April
2-6 in San Diego, Calif.
"Nastech has a directed research program that supports our co... |
| | | 03/02/05 | Nastech Announces 2004 Financial Results| BOTHELL, Wash., March 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
and year ended December 31, 2004.
Nastech ended 2004 with $74.5 million in cash, cash equivalents and
short-term investments compared to $25.1 million at December 31, 2003. In
December 2004 we completed the sale of 4.25 million shares of our common stock
at $13.50 per share and received net proceeds after expenses of approximately
$53... |
| | | 02/23/05 | Nastech to Release 2004 Financial Results and Host Webcast on Wednesday, March 2, 2005| BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its fiscal 2004 financial
results will be released on Wednesday, March 2, 2005 before the Nasdaq
National Market System opens. Management will host a conference call with
investors and financial analysts to discuss these results and to provide an
update to its clinical pipeline at 11:00 a.m. Eastern Time (8:00 a.m. Pacific
Time).
To participate in the live confe... |
| | | 02/15/05 | Nastech Announces New Presentation Time Slot for Citigroup Smith Barney Conference| BOTHELL, Wash., Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its presentation time slot at
the Citigroup Smith Barney Small and Mid Cap Conference at the Four Seasons
Hotel, Mandalay Bay, Las Vegas, Nevada, on February 17, 2005, has been changed
to 3:05 p.m. Pacific Time (6:05 p.m. Eastern Time).
The presentation will be available via webcast at the following URL
http://www.veracast.com/webcasts/sbcitigroup/sm... |
| | | 02/10/05 | Nastech to Present at Citigroup Smith Barney Conference February 17, 2005| BOTHELL, Wash., Feb. 10 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced that Steven C. Quay, M.D., Ph.D.,
chairman, president and chief executive officer, will be presenting at the
Citigroup Smith Barney Small and Mid Cap Conference at the Four Seasons Hotel,
Mandalay Bay, Las Vegas, Nevada, at 3:45 p.m. Pacific Time on February 17,
2005.
"We are pleased to have the opportunity to provide an update to the market
and set expectations for near-te... |
| | | 02/01/05 | Nastech Receives FDA Approval for Nascobal Nasal Spray for Malabsorptive and Diet-Related B12 Deficiencies| - Triggers a $2.0 MM Milestone Payment to Nastech - BOTHELL, Wash., Feb 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK), a leader in drug delivery technology,
announced the approval by the U.S. Food and Drug Administration (FDA) of
Nascobal(R) (Cyanocobalamin, USP) Nasal Spray for the treatment of vitamin B12
(cyanocobalamin) deficiency in patients with pernicious anemia, Crohn's
Disease, HIV/AIDS, and multiple sclerosis.
Na... |
| | | 01/26/05 | Nastech Pharmaceutical Company Inc. Announces Initiation of Clinical Trial for Investigational PYY3-36 Nasal Spray Under Co-Development and Co-Promotion Alliance with Merck & Co., Inc.| BOTHELL, Wash., Jan. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its partner, Merck & Co.,
Inc., has initiated a Phase I study for PYY3-36 Nasal Spray for the treatment
of obesity.
"This study being conducted by Merck builds upon Nastech's PYY clinical
program. To date, 63 subjects have received more than 900 doses of intranasal
PYY, a synthetic form of the naturally-occurring peptide," said Gordon Brandt,
M.D., Executive Vice... |
| | | 01/24/05 | Nastech to Present at Drug Delivery Partnerships Conference| BOTHELL, Wash., Jan 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced that Gordon Brandt, M.D., Executive Vice
President, Clinical Research and Medical Affairs, is presenting at the Drug
Delivery Partnerships conference in San Diego, California. Dr. Brandt's
presentation, entitled, "Creating Solutions for Enhanced Peptide and Protein
Delivery through Nastech's Drug Delivery System," is scheduled for Wednesday,
January 26 at 2:45 p.m... |
| | | 01/14/05 | Nastech to Present at Two Investor Conferences in February 2005|
Citigroup Smith Barney Small/Mid Cap Conference, February 16 and 17, Las
Vegas, NV, and BIO CEO & Investor Conference, February 23 and 24, New York
City, NY
BOTHELL, Wash., Jan. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) today announced that Steven C. Quay,
M.D., Ph.D., chairman, president and chief executive officer will be
presenting at the following upcoming investor conferences:
Ci... |
| | | 12/09/04 | Nastech Announces Completion of Its Public Offering of Common Stock| BOTHELL, Wash., Dec. 9 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) today announced the completion of its
public offering of 4,250,000 shares of common stock at a price of $13.50 per
share, with gross proceeds of approximately $57.4 million before deducting
underwriting discounts and commission and offering expenses. The underwriters
have an option, which expires on January 7, 2005, to purchase up to an
additional 637,500 shares of common stock ... |
| | | 11/24/04 | Nastech Announces Proposed Public Offering of Common Stock| BOTHELL, Wash., Nov 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today plans to offer
4,250,000 shares of common stock in an underwritten public offering pursuant
to an effective shelf registration statement. Nastech intends to grant the
underwriters an option to purchase an additional 637,500 shares of common
stock to cover over-allotments.
Citigroup Global Markets Inc. is acting as sole book-running manager fo... |
| | | 11/23/04 | Nastech Acquires Exclusive Worldwide Rights to Patents and Patent Applications for Peptide YY Analogs in the Fields of Obesity and Appetite Suppression From University of Cincinnati| BOTHELL, Wash., Nov. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today it has acquired exclusive
worldwide rights to patents and patent applications from the University of
Cincinnati covering analogs of Peptide YY, or peptide derivatives, in the
fields of obesity, appetite suppression, reducing food intake, inducing weight
loss and inducing satiety.
The agreement includes exclusive commercial rights to issued U.S. patent
5,604,203, which... |
| | | 11/08/04 | Nastech Initiates Feasibility Studies in Type 2 Diabetes and Alzheimer's Disease| BOTHELL, Wash., Nov 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced that the Company has entered into
separate agreements with two undisclosed research partners to evaluate the
development of proprietary formulations for the nasal delivery of compounds
useful for the treatment of type 2 diabetes and Alzheimer's disease.
Financial terms are not disclosed.
Nastech will utilize its proprietary Tight Junction technology to screen
i... |
| | | 11/01/04 | Nastech Receives FDA Approvable Letter for Nascobal(R) Nasal Spray| BOTHELL, Wash., Nov. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
receipt of an approvable letter from the U.S. Food and Drug Administration
(FDA) on Nascobal(R) (Cyanocobalamin, USP) Nasal Spray for the treatment of
vitamin B-12 deficiency. Nascobal Nasal Spray was developed by Nastech as an
alternative to Nascobal Nasal Gel and worldwide marketing rights to both
products were divested to Questcor Pharmace... |
| | | 10/28/04 | Nastech Updates Program for Oral Abuse-Resistant Opioids - U.S. Patent Application Published| BOTHELL, Wash., Oct. 28 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the U.S. Patent & Trademark
Office has published Patent Application No. WO 60/454253, inventors Drs. Jules
A. Shafer, President and CEO of Controlled Chemicals Inc. (CCI),
Vladislav V. Telyatnikov and Zhiwei Guo. This application stems from an
ongoing Nastech-CCI collaboration directed to "compounds and methods for
lowering the abuse potential and extending the duratio... |
| | | 10/26/04 | Nastech Announces Third Quarter 2004 Financial Results| BOTHELL, Wash., Oct. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended September 30, 2004.
The net loss for the quarter ended September 30, 2004 was $7.6 million or
$0.57 per share, compared to a net loss of $6.3 million or $0.58 per share for
the quarter ended September 30, 2003. Net loss for the nine months ended
September 30, 2004 was $22.7 million or $1.83 per share compared to net income
of $3.... |
| | | 10/25/04 | Nastech Pharmaceutical Enters into Commercialization Agreement for Nasal Calcitonin for Osteoporosis with Par Pharmaceutical| BOTHELL, Wash., Oct 25, 2004 (PRNewswire-FirstCall via COMTEX) -- Nastech Pharmaceutical Company Inc. ("Nastech") today announced that it has entered into an exclusive license and supply agreement with Par Pharmaceutical, Inc. ("Par") for U.S. distribution and marketing of Nastech's calcitonin-salmon nasal spray for the treatment of osteoporosis. This collaboration combines Nastech's strengths in preclinical and clinical product development, nasal drug formulation and delivery, and commercial-sc... |
| | | 10/14/04 | Nastech Pharmaceutical Company Inc. to Present at the Rodman & Renshaw Healthcare Conference| BOTHELL, Wash., Oct. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Rodman & Renshaw
Techvest 6th Annual Healthcare Conference on Thursday, October 28, 2004 at
8:40 a.m. ET. Steven C. Quay, M.D., Ph.D., Chairman, President and Chief
Executive Officer of Nastech will be providing a corporate overview, which
will include a review of the company's development programs. The conference
will be held at the Waldorf Astoria Hotel in New ... |
| | | 10/13/04 | Nastech to Release Third Quarter Financial Results and Host Webcast on Tuesday, October 26, 2004| BOTHELL, Wash., Oct. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its third quarter 2004
financial results will be released on Tuesday, October 26, 2004 before the
Nasdaq National Market System opens. Management will host a conference call
with investors and financial analysts to discuss these results and to provide
an update to its clinical pipeline at 11:00 a.m. Eastern Time
(8:00 a.m. Pacific Time).
To participate in the li... |
| | | 09/30/04 | Nastech Files Universal Shelf Registration Statement| BOTHELL, Wash., Sep 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK), an emerging pharmaceutical company,
announced today that it has filed a universal shelf registration statement on
Form S-3 with the U.S. Securities and Exchange Commission (SEC), pursuant to
which Nastech may issue common stock, warrants and debt securities from time
to time, up to an aggregate of $80 million. The terms of any future offering
would be establishe... |
| | | 09/27/04 | Nastech Pharmaceutical Company Inc. and Merck & Co., Inc. Announce Co-Development and Co-Promotion Alliance for Investigational PYY3-36 Nasal Spray for Treatment of Obesity| BOTHELL, Wash. and WHITEHOUSE STATION, N.J., Sept. 27
/PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. and Merck & Co.,
Inc. announced today that they have entered into a global alliance to develop
and commercialize Peptide YY 3-36 Nasal Spray (PYY), Nastech's Phase I product
for the treatment of obesity.
Under the terms of the agreement, Nastech will receive an initial cash
payment of $5 million and will be eligible to receive up to $131 million if
all development mile... |
| | | 09/27/04 | Nastech Acquires Exclusive Worldwide Rights to PYY Patent Applications for Nasal Administration From Thiakis| Company Strengthens PYY 3-36 Patent Estate for Treatment of Obesity
and Makes Equity Investment in Thiakis Limited
BOTHELL, Wash., Sept. 27 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today it has acquired exclusive
worldwide rights to the Imperial College Innovations and Oregon Health &
Science University PYY patent applications in the field of intranasal delivery
of PYY and the use of glucagon-like peptide-1 (GLP-1) used in... |
| | | 07/21/04 | Nastech Announces Second Quarter Financial Results| BOTHELL, Wash., July 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended June 30, 2004. The net loss for the quarter ended June 30, 2004 was
$7.5 million or $0.62 per share, compared to net income of $13.0 million or
$1.20 per share for the quarter ended June 30, 2003. Net loss for the six
months ended June 30, 2004 was $15.1 million or $1.26 per share compared to
net income of $10.0 million or $0.93 per s... |
| | | 07/16/04 | Nastech to Release Second Quarter Financial Results and Host Webcast On Wednesday, July 21, 2004| BOTHELL, Wash., July 16 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its second quarter 2004
financial results will be released on Wednesday, July 21, 2004 before the
Nasdaq National Market System opens. Management will host a conference call
with investors and financial analysts to discuss these results at 11:00 a.m.
Eastern Time (8:00 a.m. Pacific Time).
Please log on to http://www.nastech.com to access the live broadcast or
th... |
| | | 06/29/04 | Nastech Announces Positive Phase 1-C Clinical Results of PYY3-36 Nasal Spray for Obesity| Study demonstrates evidence of weight loss, caloric reduction and safety
BOTHELL, Wash., June 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced results from a randomized, double
blind, placebo controlled Phase 1-C dose-sequencing study of Nastech's PYY3-36
Nasal Spray for obesity, indicating the investigational product reduces
caloric intake, demonstrates weight loss over the study, and is safe and well
tolerated in clinically obese men... |
| | | 06/28/04 | Nastech Raises $12.5 Million in Sale of Common Stock and Warrants| BOTHELL, Wash., June 28 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that it has raised $12.5 million
through the sale of approximately 1.14 million shares of common stock at a
price of $11.00 per share to an institutional investor. The purchase price
represents a premium of 15% to the closing price of Nastech's common stock on
June 24, 2004, the day prior to the sale. The transaction also includes
warrants to purchase initially 511,364 sha... |
| | | 06/02/04 | Nastech Announces Successful Pre-Approval Inspection for Manufacturing of Both Nascobal(R) Nasal Spray and Calcitonin Nasal Spray| BOTHELL, Wash., June 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the U.S. Food and Drug
Administration has successfully completed the Pre-Approval Inspection (PAI) of
the Company's manufacturing facility for both the Nascobal(R) Nasal Spray
product for treatment of vitamin B-12 deficiencies and the Salmon-Calcitonin
Nasal Spray product for osteoporosis. Both product candidates are under FDA
review for marketing clearance.
"We ... |
| | | 05/26/04 | Nastech Highlights PYY Nasal Spray Development Program at 13th European Congress on Obesity| PRAGUE, Czech Republic, May 26 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced the presentation of
data from its Peptide YY 3-36 Nasal Spray (PYY) for the treatment of obesity
at the 13th European Congress on Obesity in Prague, Czech Republic.
The featured abstract "Nasal Peptide YY 3-36: Phase 1 Dose-Ranging and
Safety Study in Healthy Subjects" marks the first presentation of data from
Nastech's PYY Nasal Spray development program in the... |
| | | 05/24/04 | Nastech Acquires Cedars-Sinai Medical Center PYY Patent Estate for Treatment of Obesity| Licensing Agreement Further Strengthens Nastech's PYY Intellectual Property BOTHELL, Wash., May 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today it has acquired exclusive
worldwide rights to the Cedars-Sinai Medical Center, Los Angeles, CA (CSMC)
Peptide YY patent, patent applications, and proprietary know-how estate to
support ongoing commercialization efforts of Nastech's investigational PYY
3-36 Nasal Spray for Obesity.
... |
| | | 05/19/04 | Nastech Presents Scientific Abstracts at AAPS National Biotechnology Conference| BOTHELL, Wash., May 19 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the Company is presenting
five abstracts at the ongoing American Association of Pharmaceutical
Scientists National Biotechnology Conference in Boston, Massachusetts. Chuck
Foerder, Ph.D., Head of Analytical Services; Conor MacEvilly, Ph.D.,
Analytical Chemist; Mary Kleppe, Formulations Scientist; Rick Costantino,
Ph.D., Head of Formulations Development; and Kunyuan Cui,... |
| | | 05/18/04 | Nastech to Present at UBS Global Specialty Pharmaceuticals Conference| BOTHELL, Wash., May 18, 2004 /PRNewswire-FirstCall via Comtex/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that Steven C. Quay, M.D., Ph.D.,
Chairman, President, and Chief Executive Officer, will present at the UBS
Global Specialty Pharmaceuticals Conference on Monday, May 24, 2004 at
9:00 a.m. Eastern Time at The Grand Hyatt Hotel, New York, N.Y.
What: Nastech's presentation at the UBS Global Specialty
Pharmaceuticals Conference
... |
| | | 05/10/04 | Nastech to Present at SunTrust Robinson Humphrey Therapeutics Conference| BOTHELL, Wash., May 10 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that it will present at the
SunTrust Robinson Humphrey "Off the Cuff" Therapeutics Conference on Tuesday,
May 11, 2004 at 1:00 p.m. Eastern Time at Le Parker Meridien Hotel, New York,
N.Y.
What: Nastech's presentation at the SunTrust Robinson Humphrey
Therapeutics Conference
When: Tuesday, May 11, 2004 at 1:00 p.m. Eastern Time
Where: ww... |
| | | 05/03/04 | Nastech Initiates Intranasal Parathyroid Hormone Clinical Development| BOTHELL, Wash., May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it commenced a Phase I
clinical trial to evaluate intranasal administration of human parathyroid
hormone 1-34 (PTH1-34) in healthy subjects. The objective of the Phase I
study is to determine nasal absorption and safety of Nastech's investigational
PTH1-34 Nasal Spray formulation versus the approved subcutaneous injection.
"We are pleased to have add... |
| | | 04/21/04 | Nastech Announces the Nomination of Myron Z. Holubiak, Leslie D. Michelson, and Gerald T. Stanewick to its Board of Directors| BOTHELL, Wash., April 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has nominated Myron Z.
Holubiak, Leslie D. Michelson, and Gerald T. Stanewick to its Board of
Directors.
Mr. Holubiak is a senior executive with a broad background in the
pharmaceutical industry. He was President of Roche Laboratories, Inc. from
1998 through 2001, and was responsible for all U.S. operations including
oversight of the development and launch o... |
| | | 04/21/04 | Nastech Announces First Quarter Financial Results| BOTHELL, Wash., April 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced a net loss of $7.6 million or
$0.64 per share for the quarter ended March 31, 2004, compared to a net loss
of $2.9 million or $0.29 per share for the first quarter of 2003. The
increased net loss compared to the prior year resulted primarily from a $2.2
million decrease in revenue and $2.6 million growth in operating expenses,
primarily related to research and development... |
| | | 04/14/04 | Nastech to Release First Quarter Financial Results and Host Webcast on Wednesday, April 21, 2004| BOTHELL, Wash., April 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter 2004
financial results will be released on Wednesday, April 21, 2004 before the
Nasdaq National Market System opens. Management will host a conference call
with investors and financial analysts to discuss these results at 11:00 a.m.
Eastern Time (8:00 a.m. Pacific Time).
Please log on to http://www.Nastech.com to access the live broadcast or
t... |
| | | 03/25/04 | Nastech to Present PYY 3-36 Data at 13th European Congress On Obesity| BOTHELL, Wash., March 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that the Company has been selected
to present data on the development of its first obesity formulation program,
Peptide YY3-36 (PYY) Nasal Spray, at the 13th European Congress on Obesity,
May 26-29, in Prague, Czech Republic. The abstract is titled: Nasal Peptide
YY3-36: Phase 1 Dose-Ranging and Safety Study in Healthy Subjects. Authors
include Drs. Adrian Park and Stephe... |
| | | 03/11/04 | Nastech Receives Second U.S. Patent for FDA-Approved Mammary Aspirate Specimen Cytology Test for Breast Cancer| Non-Invasive, Non-Powered Device Draws Nipple Aspirate Fluid (NAF) from the
Breast for Cytological Examination or Molecular Analysis
BOTHELL, Wash., March 11 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of a second U.S.
Patent, No. 6,689,073 entitled, "Methods and Devices for Collecting, Handling
and Processing Mammary Fluid Samples for Evaluating Breast Diseases, Including
Cancer." The patent contains 48 claims... |
| | | 03/10/04 | Nastech Announces Fourth Quarter and 2003 Financial Results| ~Cash and Investments Grows 278% and R&D Spend Grows 47% from Prior Year~
BOTHELL, Wash., March 10 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), today announced a net loss of $5.9 million, or
$0.50 per share for the quarter ended December 31, 2003, compared to a net
loss of $5.8 million, or $0.57 per share for the fourth quarter of 2002. Total
revenue for the fourth quarter of 2003 was $911,000, a decrease of $846,000
from the fourth quarter of 2002. T... |
| | | 03/10/04 | Nastech Reports Positive PYY Obesity and Apomorphine Sexual Dysfunction Clinical Trial Data|
- Phase I-B Obesity Clinical Trial Demonstrates PYY-Related Appetite
Suppression, Calorie Reduction and an Acceptable Safety Profile -
- Phase II Maximum Tolerated Dose Erectile Dysfunction Clinical Trial
Demonstrates Apomorphine is Safe and Well Tolerated at Doses Significantly
Above Efficacious Doses -
BOTHELL, Wash., March 10 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery tech... |
| | | 03/03/04 | Nastech to Release Fourth Quarter and Year End Financial Results and Host Webcast on Wednesday, March 10, 2004| BOTHELL, Wash., Mar 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that its 2003 financial results will be released on Wednesday, March 10,
2004 before the Nasdaq National Market System opens. Nastech will host a
conference call to discuss these results and provide an update on the research
progress of the Company's Tight Junction and RNAi programs and the development
progress of the Com... |
| | | 02/24/04 | Nastech Initiates Phase Ic Dose-Sequencing Study Using PYY3-36 Obesity Drug Nasal Spray| - Multiple Doses of PYY to be Evaluated for Optimal Scheduling
Prior to Initiation of Phase II Clinical Trials -
BOTHELL, Wash., Feb. 24 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today the initiation of a Phase Ic in-clinic, parallel, multiple dose,
randomized, double-blind, placebo-controlled, dose-sequencing study using its
proprietary investigational PYY3-36 Nasal Spray for obesity. T... |
| | | 02/18/04 | Nastech to Present its PYY Obesity Program at the 6th Annual BIO CEO & Investor Conference| BOTHELL, Wash., Feb. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, today
announced that it will present its PYY obesity program during a Focus Session
on obesity at the 6th Annual BIO CEO & Investor Conference on February 24,
2004, in New York City. Steven C. Quay, M.D., Ph.D., Chairman, President and
Chief Executive Officer, will present for Nastech. The Focus Session on
obesity will begin at 3:30 p.m. Eastern ... |
| | | 02/17/04 | Nastech Announces FDA Acceptance of ANDA Filing for Calcitonin-Salmon Nasal Spray| BOTHELL, Wash., Feb 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the U.S. Food and Drug
Administration (FDA) has accepted for filing the Company's Abbreviated New
Drug Application (ANDA) for a generic Calcitonin-Salmon Nasal Spray for the
treatment of osteoporosis. The osteoporosis pharmaceutical market is
currently $7 billion and is expected to grow to $14 billion by 2011.
According to IMS, a market research firm, w... |
| | | 02/02/04 | Nastech Licenses Patents to siRNA Technology| BOTHELL, Wash., Feb 2, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that it has received a world-wide, non-exclusive license to the Fire et
al. patents and patent applications titled "Genetic Inhibition by
Double-Stranded RNA" (including U.S. Patent # 6,506,559 B1) from the Carnegie
Institute of Washington, D.C. Under this license, Nastech plans to use the
small interfering RNA (siRNA) t... |
| | | 01/20/04 | Nastech Initiates Dose-Range Finding Calorie Reduction Study Using PYY Obesity Drug Nasal Spray| Inter- and Intra-Subject Variability of Pharmacokinetic and Pharmacodynamic Parameters (Duration of Appetite Suppression and Calorie Reduction) To Be Assessed BOTHELL, Wash., Jan 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the initiation of a dose-range
finding study in 12 overweight adult subjects using its investigational
PYY3-36 Nasal Spray for obesity. The five way crossover, randomized, double
blind, placebo-controll... |
| | | 12/30/03 | Nastech and Questcor Announce Submission of NDA for Nascobal(R) Nasal Spray| BOTHELL, Wash. and UNION CITY, Calif., Dec. 30 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in drug delivery
technology, and Questcor Pharmaceuticals, Inc. (Amex: QSC), a specialty
pharmaceuticals product company, announced today the submission to the U.S.
Food and Drug Administration (FDA) of a New Drug Application (NDA) seeking
marketing approval for Nascobal(R) (cyanocobalamin) Nasal Spray for treatment
of vitamin B12 deficiency. Nascobal(R) Na... |
| | | 12/23/03 | Nastech Submits ANDA for Calcitonin Nasal Spray| BOTHELL, Wash., Dec. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that it has submitted an Abbreviated New Drug Application (ANDA) for
Calcitonin-Salmon Nasal Spray for osteoporosis to the U.S. Food and Drug
Administration (FDA).
Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive
Officer of Nastech, stated, "We are pleased to have submitted the calcitonin
ANDA during the fourt... |
| | | 12/18/03 | Nastech Pharmaceutical Company Inc. Files Shelf Registration Statement| BOTHELL, Wash., Dec 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that it has filed a shelf registration statement on Form S-3 with the
U.S. Securities and Exchange Commission (SEC), pursuant to which the Company
may issue common stock and warrants from time to time, up to an aggregate of
$30 million. The terms of any future offering would be established at the
time of the offering. ... |
| | | 12/17/03 | Nastech Reports Results of Tight Junction Research At 43rd Meeting of the American Society of Cell Biology| BOTHELL, Wash., Dec 17, 2003 /PRNewswire-FirstCall via Comtex/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, today
presented the results of important new research on the structure and function
of tight junctions (TJ), cell-to-cell connections that regulate the passage of
molecules and cells across tissue barriers. The data was presented at the
43rd meeting of the American Society of Cell Biology (ASCB) in San Francisco
by Kunyan Cui, Ph.D., S... |
| | | 12/11/03 | Gregory L. Weaver, Chief Financial Officer of Nastech Pharmaceutical Company Inc., Elected To WBBA Board of Directors| BOTHELL, Wash., Dec. 11 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that the Washington Biotechnology & Biomedical Association (WBBA) has
elected Greg Weaver, Chief Financial Officer of Nastech, to its Board of
Directors.
"We are pleased to welcome Greg to the Board of Directors of the WBBA and
are grateful for his and Nastech's commitment to the growth of biotechnology
in the Pacific Northwe... |
| | | 11/17/03 | Webcast Alert: Nastech Pharmaceutical Company Inc. Presentation at the Informed Investors Virtual Drug Delivery Stocks Forum to be Webcast on Thursday, November 20, 2003, 9:00 a.m. ET| BOTHELL, Wash., Nov. 17 /PRNewswire/ -- Nastech Pharmaceutical Company
Inc. (Nasdaq: NSTK) will webcast the following presentation:
What: Steven C. Quay, M.D., Ph.D, Chairman, President and Chief
Executive Officer of Nastech will give a presentation at the
Informed Investors Virtual Drug Delivery Stocks Forum
Forum Keynote by Nicole Yost, Editor of Target World Drug Delivery
News
When: November 20, 2003 @ 9:00 a.m. E... |
| | | 11/13/03 | Nastech Demonstrates Successful Delivery of Obesity Drug Nasal Spray in Clinical Trial| PYY 3-36 Nasal Spray Mimics Natural, Post-Meal Blood Levels and Is Well
Tolerated
BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the completion and interim results
for a Phase I dose-ranging study demonstrating the successful nasal delivery
of PYY 3-36 (PYY) for treatment of obesity. The study, involving 15 healthy
subjects in five rising dose groups, was conducted at the Hammersmi... |
| | | 11/13/03 | Nastech Announces Third Quarter Financial Results| BOTHELL, WA, Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), today announced a net loss of $0.58 per share for
the quarter ended September 30, 2003, compared to a net loss of $0.34 per
share for the third quarter of 2002. The increased net loss for the third
quarter resulted primarily from a $1.5 million decrease in license and
research fee revenue and growth in research and development expense partially
offset by a decrease in sales and marketing expe... |
| | | 11/06/03 | Nastech to Release Third Quarter Financial Results and Host Webcast On Thursday, November 13, 2003| BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that its Third Quarter 2003 financial results will be released on
Thursday, November 13, 2003 before the Nasdaq National Market System opens.
Nastech will host a conference call to discuss these results with financial
analysts at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) and will webcast
the call live on the Company's Internet sit... |
| | | 10/14/03 | Nastech Presents Nasal Spray PYY 3-36 Data at 2003 Annual Meeting of North American Association for the Study of Obesity (NAASO)| BOTHELL, Wash. and FT. LAUDERDALE, Fla., Oct 14, 2003 /PRNewswire-FirstCall via Comtex/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in drug delivery
technology, today announced the presentation of data on the development of its
nasal spray formulation of PYY 3-36 (PYY) at the 2003 Annual Meeting of the
North American Association for the Study of Obesity being held in Ft.
Lauderdale, Florida. The data reported describe formulation, preclinical, and
clinical studies conduc... |
| | | 09/30/03 | Paul H. Johnson, Ph.D., Joins Nastech as Senior Vice President, Research & Development and Chief Scientific Officer| BOTHELL, Wash., Sept. 30 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, is pleased
to announce that Dr. Paul H. Johnson, Ph.D., has joined the Company as Senior
Vice President, Research & Development and Chief Scientific Officer effective
immediately. He will report to Steven C. Quay, M.D., Ph.D., Chairman,
President and Chief Executive Officer.
"Paul's extensive, broad-based experience in pharmaceutical develop... |
| | | 09/23/03 | Nastech Initiates Intranasal PYY3-36 Phase I Clinical Trial| -First Non-Intravenous Infusion Dosage Form of PYY To Enter Human Clinical
Trials-
BOTHELL, Wash., Sept. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, announced
today that it has commenced a Phase I clinical trial at Hammersmith Hospital,
London, UK, to evaluate the intranasal administration of peptide YY3-36 (PYY)
in the treatment of obesity. The objective of the Phase I dose ... |
| | | 09/18/03 | Nastech to Present at the UBS Global Life Sciences Conference| BOTHELL, Wash., Sept. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), today announced that it will present at the UBS
Global Life Sciences Conference. Jade R. Brown, Vice President, Marketing and
Business Development, will give the presentation on Tuesday, September 23,
2003, at 8:00 a.m. Eastern Time. The conference will be held at the Plaza
Hotel in New York City and will be webcast live.
What: Nastech's presentation at the UBS Global Life Sc... |
| | | 09/17/03 | Nastech to Present PYY 3-36 Data at Upcoming Annual Meeting of the North American Association for the Study of Obesity| -Abstract Published in Obesity Research-
BOTHELL, Wash., Sept. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in drug delivery technology, today
announced that the Company will present data on the development of its first
obesity compound, an intranasal dosage form of Peptide YY3-36 (PYY). Gordon
Brandt, M.D., Executive Vice President of Science and Clinical Development,
will present the data at the annual meeting of the North American Asso... |
| | | 09/16/03 | Jade R. Brown Promoted to Vice President, Marketing and Business Development at Nastech| BOTHELL, Wash., Sep 16, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), announced today that Mr. Jade R. Brown has been
promoted to Vice President of Marketing and Business Development. Mr. Brown
was previously Senior Director of Marketing and Business Development. He will
continue to report to Steven C. Quay, M.D., Ph.D., Chairman, President, and
Chief Executive Officer.
"I am delighted to announce this promotion, which reflects Jade's
ex... |
| | | 09/04/03 | Nastech Closes $11 Million Private Placement| BOTHELL, Wash., Sept. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has completed a private
placement of equity securities to institutional investors totaling
$11.0 million in gross proceeds. The net proceeds will be used for general
corporate purposes, including working capital. Lehman Brothers Inc. acted as
exclusive Placement Agent for the financing.
In the private placement, the Company issued 1.513 million shares of
comm... |
| | | 08/06/03 | Nastech Announces Second Quarter Earnings of $1.20 Per Share| BOTHELL, Wash., Aug 06, 2003 /PRNewswire-FirstCall via Comtex/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), today announced that fully diluted earnings per
share for the second quarter of 2003 was $1.20 versus a loss of $0.15 per
share for the second quarter of 2002. Total revenue increased 330% to $15.7
million in the second quarter of 2003 compared to same period last year. The
second quarter 2003 financial results include the following:
* Revenue recognition of th... |
| | | 07/30/03 | Nastech to Release Second Quarter Financial Results And Host Webcast on Wednesday, August 6th, 2003| BOTHELL, Wash., Jul 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in nasal drug delivery technology,
announced today that its Second Quarter 2003 financial results will be
released on Wednesday, August 6, 2003 before the Nasdaq national market system
opens. Nastech will host a conference call to discuss these results with
financial analysts at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) and will
webcast the call live on the ... |
| | | 07/29/03 | Rick Costantino, Ph.D., Joins Nastech as Senior Research Scientist| BOTHELL, Wash., July 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in nasal drug delivery technology, is
pleased to announce that Henry R. "Rick" Costantino, Ph.D., has joined the
Company as Senior Research Scientist, effective immediately. He will report
to Gordon Brandt, M.D., Executive Vice President of Science and Clinical
Development.
"Rick's extensive experience in industrial and academic research and his
expertise in protein and pe... |
| | | 07/28/03 | Nastech Forms Tight Junction Scientific Advisory Board| BOTHELL, Wash., July 28 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in nasal drug delivery technology, today
announced the formation of a Tight Junction Scientific Advisory Board (TJSAB)
to assist the Company in expanding its research in tight junctions and
identifying potential commercial opportunities.
The founding members of the TJSAB are Daniel A. Goodenough, Ph.D., Harvard
Medical School, James M. Anderson, Ph.D., M.D., University of No... |
| | | 07/24/03 | Nastech Receives Notice of Allowance For Apomorphine Patent| BOTHELL, Wash., July 24 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it as received a "Notice of
Allowance" from the U.S. Patent and Trademark Office for a patent application
relating to "Nasal Delivery of Apomorphine." The allowed application contains
twelve claims and is directed to compositions of apomorphine or a chemically
modified equivalent or pharmaceutical salts thereof, which can be used to
treat sexual dysfunction including er... |
| | | 07/16/03 | Cytyc Acquires Exclusive Patent Rights to Nastech's Mammary Aspirate Device| BOXBOROUGH, Mass. and BOTHELL, Wash.--(BUSINESS WIRE)--July 16,
2003--Cytyc Corporation (CYTC) and Nastech Pharmaceutical
Company Inc. (Nasdaq NMS: NSTK), a leader in nasal drug delivery
technology, announced today an agreement under which Cytyc will
acquire exclusive world-wide patent rights to products that make use
of Nastech's FDA-approved Mammary Aspirate Specimen Cytology Test
(MASCT). The MASCT is a non-invasive, non-powered device that draws
Nipple Aspirate Fluid (NAF) from the br... |
| | | 06/17/03 | Nastech Agrees to Sell Nascobal(R) to Questcor Pharmaceuticals, Inc.| - Nastech to Receive $14.2 Million for the Transaction in 2003 and Up to $18.2 Million in Total - BOTHELL, Wash., Jun 17, 2003 /PRNewswire-FirstCall via Comtex/ -- Nastech Pharmaceutical Company, Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, announced today that Questcor Pharmaceuticals, Inc.
(Amex: QSC) is acquiring Nastech's Nascobal(R) product, including the FDA-
approved Nascobal(R) (Cyanocobalamin USP) nasal gel and the Nascobal(R) nasal
spray, which is pending FDA a... |
| | | 06/09/03 | Nastech Announces Research Results From Its Tight Junction Paracellular Drug Delivery Program| - Technology Has Potential Utility in Cancer Treatment -
BOTHELL, Wash., June 9 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, today announced research findings from its tight junction
paracellular drug delivery technology program. The results were accepted for
presentation at the 19th International Congress of Biochemistry & Molecular
Biology in Toronto, Canada and were scheduled for presentation in July 200... |
| | | 06/04/03 | Nastech Initiates Phase II Intranasal Apomorphine Trial for Male Erectile Dysfunction| BOTHELL, Wash., June 4 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, today announced initiation of a Phase II multi-center,
double-blind, randomized, placebo-controlled, dose-ranging safety study using
its investigational intranasal apomorphine hydrochloride for treatment of male
erectile dysfunction (ED). Approximately 120 subjects ages 50 and over with or
without erectile dysfunction will be included in the study... |
| | | 05/29/03 | Nastech Reports Positive Female Sexual Dysfunction Phase II Efficacy Data with Intranasal Apomorphine| BOTHELL, Wash., May 29 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, today reported results from a Phase II At-Home clinical
trial using its investigative intranasal formulation of apomorphine to treat
female sexual dysfunction (FSD). FSD is defined as persistent or recurring
reduction of sex drive or aversion to sexual activity, difficulty becoming
aroused, inability to reach orgasm, and pain during sexual interco... |
| | | 05/14/03 | Nastech Pharmaceutical Company Inc. Reports Solid First Quarter 2003 Financial Results| Quarterly Revenue Increased 53% and Cash or Equivalents Increased 87% BOTHELL, Wash., May 14, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, today announced financial results for the first quarter
ended March 31, 2003.
Total revenue for the first quarter of 2003 was $2.3 million, an increase
of 53 percent, or $800,000, from the first quarter of 2002, and an increase of
28 percent, or $500,000, fr... |
| | | 05/13/03 | Webcast Alert: Nastech Pharmaceutical Company Inc. Announces First Quarter 2003 Financial Results Conference Call Webcast| SEATTLE, May 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical Company
Inc. (Nasdaq: NSTK) announces the following Webcast:
WHAT: Nastech Pharmaceutical Company's First Quarter 2003 Financial
Results Conference Call
WHEN: 05/14/03 @ 4:30 p.m. Eastern
WHERE: http://www.firstcallevents.com/service/ajwz381465458gf12.html
HOW: Live over the Internet -- Simply log on to the web at the
address above... |
| | | 05/06/03 | Nastech to Release First Quarter Financial Results and Host Webcast On Wednesday, May 14, 2003| BOTHELL, Wash., May 6 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, announced today that its First Quarter 2003 financial
results will be released on Wednesday, May 14, 2003 after the close of the
Nasdaq national market system. Nastech will host a conference call to discuss
these results with financial analysts at 4:30 p.m. Eastern Time (1:30 p.m.
Pacific Time) and will webcast the call live on the Company's Inter... |
| | | 04/29/03 | Nastech Announces Nomination of J. Carter Beese, Jr., Former SEC Commissioner and Alex. Brown International Chairman, to Its Board of Directors| BOTHELL, Wash., Apr 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, today announced that it has nominated J. Carter Beese,
Jr. to its Board of Directors, to be voted on at the 2003 Annual Meeting of
Shareholders. Mr. Beese was the 71st Commissioner of the U.S. Securities and
Exchange Commission (SEC) from 1992 to 1994 and is currently President of
Riggs Capital Partners, a venture fund that manage... |
| | | 04/17/03 | Nastech Reacquires All Development and Commercialization Rights for Intranasal Apomorphine Following Pfizer-Pharmacia Merger| BOTHELL, Wash., April 17 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery, announced today that it has reacquired all development and
commercialization rights for intranasal apomorphine from Pharmacia following
the Pfizer-Pharmacia merger pursuant to the terms of the Divestiture Agreement
between Nastech and Pharmacia. This reacquisition gives Nastech control of
the apomorphine clinical development program for erectile dysfuncti... |
| | | 02/26/03 | Nastech Pharmaceutical Company Inc. Reports 2002 Fourth Quarter And Year-End Financial Results| BOTHELL, Wash., Feb 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in nasal drug delivery,
today announced financial results for the fourth quarter and fiscal year ended
December 31, 2002.
The fourth quarter 2002 net loss was $5.8 million, or $0.57 per share, compared
with a net loss of $3.0 million, or $0.34 per share for the fourth quarter 2001.
For the year ended December 31, 2002, the net loss was $13.5 million or $1.34
p... |
| | | 01/27/03 | Nastech to Reacquire All Intranasal Apomorphine Product Licenses and Intellectual Property and Receive $13.5 Million from Pharmacia|
~ FTC Review of Pfizer/Pharmacia Merger is
Catalyst for Divestiture Agreement ~
BOTHELL, Wash., Jan. 27 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today a
divestiture agreement with Pharmacia Corporation (NYSE: PHA) under which
Nastech will reacquire all development and marketing rights to intranasal
apomorphine for the treatment of erectile dysfunction (ED) and female sexual
dys... |
| | | 01/22/03 | Jade R. Brown Joins Nastech as Senior Director, Marketing & Business Development|
BOTHELL, Wash., Jan. 22 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced the
appointment of Jade R. Brown as Senior Director, Marketing & Business
Development. Mr. Brown brings 13 years of pharmaceutical marketing and
business development experience at Eli Lilly and Company to Nastech. He will
report to Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief
Executive Officer.
In this newly created position, Mr. B... |
| | | 01/21/03 | NASTECH DEMONSTRATES SUCCESSFUL DELIVERY OF INTRANASAL SUMATRIPTAN FOR MIGRAINE|
~Data
indicate nearly double the amount of Sumatriptan delivered with Nastech's
investigational nasal formulation ~
BOTHELL,
WA, January 21, 2003
– Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK), a leader
in formulation science and nasal drug delivery, announced today positive
results of Nastech's investigational nasal dosage form of sumatriptan
for treatment o... |
| | | 01/16/03 | Paul G. Lunn, Esq., Joins Nastech as Patent Counsel|
BOTHELL, Wash., Jan. 16 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced the
appointment of Paul G. Lunn, Esq., as in-house Patent Counsel. Mr. Lunn
brings almost 20 years of experience in the field of patent law to Nastech.
He will report to Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief
Executive Officer.
"Paul has prosecuted over 200 US patents, including issuance of key
patents for GM-CSF (granulocyte-... |
| | | 12/17/02 | Nastech’s Nasal Spray Formulation Of Cyanocobalamin Demonstrates Bioequivalence To Nascobal® Nasal Gel| -NDA Filing Expected First Half 2003-
BOTHELL, WA, December 17, 2002 — Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) today announced positive results from a bioequivalence study showing that its investigational nasal spray dosage form of cyanocobalamin (vitamin B12) is bioequivalent to Nascobal® (Cyanocobalamin, USP) nasal gel. Nascobal is Nastech's FDA approved therapy for the treatment of vitamin B12 deficient patients with Crohn's disease, Colitis, pernicious anemia, and ce... |
| | | 12/10/02 | Nastech Reports Positive Phase Ii Trial Results With Intranasal Morphine Gluconate In Cancer Patients| ~Potential Advancement for Treatment of Breakthrough Pain~
BOTHELL, WA, December 10, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) today announced positive results from a Phase II clinical trial with intranasal morphine gluconate, its patented investigational product for treatment of breakthrough pain in opioid tolerant cancer patients. Results indicate that intranasal morphine gluconate was rapidly absorbed and produced meaningful pain relief. There were no serious adve... |
| | | 12/03/02 | Gordon Brandt, M.D., Joins Nastech As Executive Vice President Of Science And Clinical Development| ~ New Appointment Further Strengthens Nastech's Executive Management Team ~
BOTHELL, WA – December 3, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) today announced the appointment of Gordon Brandt, M.D., as Executive Vice President of Science and Clinical Development. Dr. Brandt brings more than 20 years of experience in the medical field to Nastech. He will report to Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief Executive Officer.
“Gordon's extens... |
| | | 11/08/02 | Nastech Reports Third Quarter 2002 Financial Results| BOTHELL, WA, November 8, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK), a leader in nasal drug delivery technology, today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2002.
The Company reported that, for the third quarter ended September 2002, revenue increased $1.2 million, or 145 percent, to $2.0 million compared to revenue of $809,000 for the third quarter of 2001. For the nine months ended September 30... |
| | | 10/23/02 | Nastech Issues Statement Concerning Pfizer’s Sexual Dysfunction Patent| BOTHELL, WA, October 23, 2002 – In response to numerous shareholder inquiries, Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) today issued the following statement from Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer:
“Earlier today it was reported that Pfizer Inc. has received a broad U.S. patent covering the way Viagra® and other PDE-5 inhibitors work to treat impotence and immediately filed two lawsuits to block rivals from selling competing produc... |
| | | 10/18/02 | Nastech To Announce Commercial Availability Of Nascobal® For Treatment Of Vitamin B12 Deficiency In Crohn’s Disease At American College Of Gastroenterology Annual Meeting| BOTHELL, WA, October 18, 2002 - Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) will announce the commercial availability of Nascobal® (Cyanocobalamin, USP) Gel for the treatment of vitamin B12 deficiency in Crohn's disease this Sunday at the 67th Annual Meeting of the American College of Gastroenterology and Postgraduate Course in Seattle, Washington. Nastech is an exhibitor at the ACG meeting, where it is making available Nascobal® product monographs, FAQ sheets, patient instructions, a... |
| | | 10/10/02 | Nastech To Present At Serono Satellite Meeting In Torino, Italy| BOTHELL, WA, October 10, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) announced today that Dilip Worah, Chief Scientific Officer, will make a scientific presentation tomorrow at the Serono-sponsored Satellite Meeting to the Fourth International Joint Conference of the International Society for Interferon and Cytokine Research, International Cytokine Society, Society for Leukocyte Biology, and European Cytokine Society in Torino, Italy. The topic of the Satellite Meeting is drug ... |
| | | 10/02/02 | Nastech Receives $1.0 Million Apomorphine Milestone Payment From Pharmacia| BOTHELL, WA, October 2, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) has received a $1.0 million contractual milestone payment from Pharmacia Corporation under terms of its worldwide Collaboration and License Agreement for intranasally administered apomorphine for male and female sexual dysfunction.
“This milestone payment marks the achievement of another discrete step in our intranasal apomorphine program,” stated Steven C. Quay, M.D., Ph.D., Chairman, President and C... |
| | | 10/01/02 | Nastech Reacquires Nascobal® (Cyanocobalamin, USP) Gel From Schwarz Pharma And Signs Contract Sales Agreement With Cardinal Health| BOTHELL, WA, October 1, 2002 - Nastech Pharmaceutical Company Inc. (NASDAQ NMS: NSTK) announced it has reacquired all product, patent, trademark, licensing and regulatory rights for Nascobal® in the United States from Schwarz Pharma. Under terms of the acquisition agreement, Nastech will pay Schwarz a total of $8.75 million plus interest in installments over a four-year period, including an upfront payment of $1.5 million. Under the agreement, Schwarz relinquishes its rights to receive any consi... |
| | | 09/18/02 | Nastech Receives U.S. Patent For Nasal Delivery Of Morphine Gluconate For Treatment Of Breakthrough Pain| BOTHELL, WA, September 18, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) announced today that it was issued U.S. Patent No. 6,451,848, entitled, “Compositions and Methods Comprising Morphine Gluconate.” The patent contains 21 claims relating to a pharmaceutical composition of morphine gluconate or chemical equivalent thereof. The patent includes a method of making morphine gluconate, or chemical equivalent thereof, and a method for eliciting an analgesic or anesthetic response.
... |
| | | 08/20/02 | Nastech Receives U.S. Patent For Nasal Delivery Of Apomorphine For Sexual Dysfunction| BOTHELL, WA, August 20, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK) announced today that it was issued U.S. Patent No. 6,436,950, entitled, “Nasal Delivery of Apomorphine.” The patent contains thirteen claims and is directed to compositions of apomorphine or a chemically modified equivalent or pharmaceutical salt and to methods of treating sexual dysfunction, including erectile dysfunction. Apomorphine is a potent dopamine agonist that promotes erectile function by stimulating ... |
| | | 08/14/02 | Nastech Reports Second Quarter Results| BOTHELL, WA, August 14, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq National Market: NSTK), a leader in nasal drug delivery technology, today reported operating highlights and financial results for the second quarter and first half of fiscal 2002 ended June 30, 2002. Highlights included:
APOMORPHINE — Nastech's license agreement with Pharmacia for the development and commercialization of our intranasal apomorphine product is ongoing and the development program is receiving the ac... |
| | | 07/02/02 | Nastech Announces FDA Approval Of Nascobal® Labeling Supplement To Include Maintenance Of Hematologic Status In Patients With Hiv Infection, Aids, Multiple Sclerosis And Crohn’s Disease| BOTHELL, WASH., July 2, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement to the Nascobal® NDA that states that Nascobal can be used in patients with HIV, AIDS, multiple sclerosis, and Crohn's disease, conditions which can result in vitamin B12 deficiency, and for which Nascobal is indicated to maintain hematologic status. Nascobal® is FDA approved and has been marketed in the U.S. by Schw... |
| | | 07/01/02 | Nastech Terminates License And Supply Agreement With Schwarz Pharma For Nascobal®| Nastech Sees Significant Growth Opportunity For Its FDA Approved Intranasal Vitamin B12 Product
BOTHELL, WASH., July 1, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that under the terms of its License and Supply Agreement with Schwarz Pharma, Inc. for Nascobal®, it served a Notice of Termination, and made a demand for arbitration. Nastech alleges that Schwarz breached the agreement by failing to promote Nascobal in the marketplace as required by the Agreeme... |
| | | 07/01/02 | Nastech Added To Russell 3000® Index| BOTHELL, WASH., July 1, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced that it has been added to the Russell 3000, Index of publicly traded companies. Official index membership will remain in place for one year. The addition of Nastech's stock was part of the annual reconstitution of the Russell indexes. Membership in Russell's 21 U.S. equity indexes, which are widely used as benchmarks for investment strategies, is determined by market capitalization and style attribu... |
| | | 06/05/02 | Nastech Receives $2.0 Million Apomorphine Milestone Payment From Pharmacia| BOTHELL, WASH., June 5, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) has received a $2.0 million contractual milestone payment from Pharmacia Corporation (NYSE: PHA) under terms of its worldwide Collaboration and License Agreement for intranasally administered apomorphine for sexual dysfunction.
“This milestone payment marks achievement of a discrete step in the intranasal apomorphine program,” stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Off... |
| | | 06/03/02 | Nastech Pharmaceutical Company Inc. To Present At UBS Warburg Global Specialty Pharmaceuticals Conference| BOTHELL, WASH., - June 3, 2002 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced that Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief Executive Officer, will be presenting at the UBS Warburg Global Specialty Pharmaceuticals Conference in New York City at 4:00 pm EDT on Wednesday, June 5, 2002. The presentation will be webcast live through the following web site: http://webcast.mediaondemand.com/ubs/20020605.
An archived version of the presentation will als... |
| | | 05/22/02 | Nastech Reports Positive Pre-Clinical Data On Alzheimer’s Disease Research Program| ~ Acetylcholine Esterase Inhibitor Being Assessed For Direct-To-Brain Delivery By Intranasal Administration ~
Bothell, Wash. – May 22, 2002 – Steven C. Quay, M.D., Ph.D., Chairman, President, and Chief Executive Officer of Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), presented pre-clinical data from the Company's intranasal Acetylcholine Esterase inhibitor (AChE-I) research program at yesterday's Second Annual Panel Discussion on Alzheimer's Disease hosted by Cold Spring Harbor... |
| | | 05/20/02 | Gregory L. Weaver Joins Nastech As Chief Financial Officer| ~ New Appointment Further Strengthens Nastech's Executive Management Team ~
HAUPPAUGE, N.Y. – May 20, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced the appointment of Gregory L. Weaver as Chief Financial Officer. Mr. Weaver brings 20 years of senior level financial, managerial, and strategic business development experience to Nastech, including seven years in the healthcare industry.
“Gregory Weaver's extensive management and business development exp... |
| | | 05/15/02 | Nastech Pharmaceutical Company Plans Facilities Expansion And Relocation Of Corporate Headquarters| HAUPPAUGE, N.Y. – May 15, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced a planned expansion of its research facilities in Bothell, Washington and the relocation of its corporate headquarters to Bothell. Occupancy of the 27,000 square foot facility will begin in June and continue through the end of 2002. The new facility will also include manufacturing capacity for up to 50 million dosage units per year, a significant increase over current capacity.
Nastech curr... |
| | | 05/07/02 | Nastech Announces First Quarter Results| HAUPPAUGE, N.Y., May 7, 2002 — Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced a net loss of $2.8 million, or ($0.29) a share basic and diluted, on revenues of $1.5 million for the first quarter ended March 31, 2002, versus a year ago net loss of $2.3 million, or ($0.33) a share, on revenues of $717,000.
During the first quarter, the Company received an upfront payment from our intranasal apomorphine agreement with Pharmacia of $3.0 million. In accordance with SAB No.... |
| | | 04/30/02 | Nastech Pharmaceutical Inc. To Present At CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference| HAUPPAUGE, N.Y. – April 30, 2002– Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced that Steven C. Quay, M.D., Ph.D., Chairman, President & CEO will be presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York City on Wednesday, May 1, 2002 at 4:30PM EDT.
The presentation will be webcast live through the following web site: http://webcast.ibeam.com/starthere.asp?pres=19173&template=cibc&exit=http://www.nastech.com An ar... |
| | | 04/03/02 | Nastech Receives $2.0 Million Apomorphine Development Milestone Payment From Pharmacia| HAUPPAUGE, NEW YORK, April 3, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq:NSTK) announced today that it has received a $2.0 million development milestone payment from Pharmacia Corporation under their recently announced worldwide Collaboration and License Agreement for intranasally administered apomorphine for sexual dysfunction.
“Our collaboration with Pharmacia in the intranasal apomorphine clinical development program is proceeding on schedule,” stated Steven C. Quay, M.D., Ph.... |
| | | 03/21/02 | Nastech Demonstrates Successful Delivery Of Nasally Administered Interferon Beta-1a In Man| ~ Potential Advancement for Multiple Sclerosis Treatment ~
HAUPPAUGE, NEW YORK, March 21, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced interim results from its Phase I pharmacokinetic, pharmacodynamic, safety and tolerance study demonstrating the successful nasal delivery of Interferon beta-1a. The Company believes that additional research may provide multiple sclerosis patients with an easy-to-use, non-invasive alternative to injectable Interferon beta.
... |
| | | 03/18/02 | Nastech Receives $5 Million Equity Investment From Pharmacia| HAUPPAUGE, NEW YORK, March 18, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq:NSTK) announced today that it has received a $5 million investment from Pharmacia in exchange for 250,000 shares of Nastech common stock, a per share purchase price of $20.00. This purchase is pursuant to the License Agreement dated February 1, 2002 between Nastech and Pharmacia and the Investment Agreement dated February 1, 2002 between Nastech and Pharmacia. Pharmacia's purchase of the shares follows Federal Trad... |
| | | 02/19/02 | Nastech Reports 2001 Financial Results| HAUPPAUGE, NEW YORK, FEBRUARY 19, 2002 – Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the fourth quarter and fiscal year ended December 31, 2001.
“Last year, Nastech committed to an ambitious growth strategy and we are pleased to report that all of our key corporate objectives were met, including an exclusive worldwide development and commercialization agreement with Pharmacia for our nasally administered apomorphine for erectile dysfunction (... |
| | | 02/04/02 | Nastech And Pharmacia Reach Worldwide Agreement To Develop And Market Nasally Administered Apomorphine| HAUPPAUGE, NEW YORK and PEAPACK, NEW JERSEY (February 4, 2002) — Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) and Pharmacia Corporation (NYSE: PHA) announced today an agreement for the development and marketing of Nastech's proprietary nasally administered apomorphine product for the treatment of erectile dysfunction (ED) and female sexual dysfunction (FSD).
Apomorphine is a potent dopamine agonist that promotes erectile function by stimulating the D1/D2 class of dopamine recepto... |
| | | 01/23/02 | Nastech Receives Approval To Market Nascobal® In Sweden| Regulatory Submissions in Other EU Countries Planned
HAUPPAUGE, NEW YORK, January 23, 2002 — Nastech Pharmaceutical Company Inc. (NASDAQ: NSTK) announced today that the Swedish Medical Products Agency (MPA) has granted marketing authorization for the sale of Nascobal® (Cyanocobalamin USP) Gel for Intranasal Administration to treat Vitamin B12 malabsorption. Nastech intends to market the product through a European licensee.
“Regulatory approval in Sweden is an important first st... |
| | | 01/08/02 | FDA Clears New Patented Test For Rapid Identification Of Breast Cancer Risk Factors| Nastech Intends for Non-Invasive Test to Become Adjunct to Mammography and Physical Examination in Breast Disease Detection and Management
HAUPPAUGE, NEW YORK, January 8, 2002 — Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its non-invasive, patented Mammary Aspiration Specimen Cytology Test (MASCT) device for potential early detection of breast cancer.
The device was de... |
| |
|
|
|
